KOL | Hiroshi FujishimaDepartment of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa 230-0063, Japan;, fujishima117@gmail.com | Department of Ophthalmology, Keio University ... |
Kol currículo para Hiroshi Fujishima
| Year | |
|---|---|
| 2021 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa 230-0063, Japan;, Ophthalmology, Tsurumi University Dental Hospital, Yokohama, Kanagawa, Japan |
| 2020 | Department of Ophthalmology, Keio University School of Medicine, Tokyo 160-0016, Japan;, (E.S.);, (N.A.);, (Y.O.) Fujishima Eye Clinic, Niigata 949-6600, Japan |
| 2019 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Tsurumi-ku 230-8501, Kanagawa, Japan;, (N.K.);, (A.S.);, (H.F.) Tsurumi University School of Dental Medicine, Yokohama, Japan |
| 2016 | Department of Ophthalmology, Tsurumi University Dental Hospital, Kanagawa, Japan |
| 2015 | From the *Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa; and †Department of Ophthalmology, Tokyo Saiseikai Central Hospital; and ‡J&J Ocular Surface and Visual Optics Department, Keio University School of Medicine, Tokyo, Japan. |
| 2014 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Yokohama, Japan |
| 2012 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa |
| 2011 | Department of Ophthalmology, Tsurumi University Dental Hospital, Kanagawa, Japan. |
| 2010 | Department of Ophthalmology, International University of Health and Welfare, Mita Hospital, Tokyo, Japan. |
| 2009 | Department of Ophthalmology, Keio University, Tokyo, Japan. |
| 2008 | Department of Ophthalmology, International University of Welfare, Mita Hospital, Tokyo, Japan |
| 2007 | International University of Health and Welfare, Department of Ophthalmology, Mita Hospital, 1-4-3 Mita, Minato-ku, Tokyo 108-8329, Japan. |
| 2006 | From the *Department of Ophthalmology, Tokyo Dental College, Ichikawa General Hospital, Ichikawa, Japan; †Keio University School of Medicine, Tokyo, Japan; and ‡Hara Eye Clinic, Otawara, Tochigi Prefecture, Japan. Department of Ophthalmology, Keio University School of Medicine |
| 2005 | From the Department of Ophthalmology, Keio University, Tokyo, Japan; the Department of Ophthalmology, Tokyo Dental College, Sugano 5-11-13, Ichikawa, Chiba 272-8513, Japan |
| 2004 | From the Departments of *Ophthalmology and †Dermatology, Tokyo Dental College, Ichikawa, Chiba, Japan. Department of Ophthalmology, Keio University, Tokyo, Japan |
| 2003 | Department of Ophthalmology, Tokyo Dental College, Chiba, Japan |
| 2002 | Department of Ophthalmology, Tokyo Dental College, Sugano, Ichikawa, Japan. |
| 2001 | From the Departments of Ophthalmology (N.A-K., K.F., K.T., K.U., H.F.) and Dermatology (S.T.), Tokyo Dental College, Chiba, Japan. |
| 1998 | Department of Ophthalmology, Tokyo Dental College, Ichikawa, Chiba, Japan. |
| 1997 | Department of Ophthalmology, Tokyo Dental College, Chiba |
| 1996 | Department of Ophthalmology, Tokyo Dental College; Department of Ophthalmology, Keio University School of Medicine |
| 1995 | Chiba, Tokyo, and Akita, Japan Department of Ophthalmology Tokyo Dental College, Chiba |
| 1994 | Department of Ophthalmology, School of Medicine, Keio University, Tokyo, Japan. |
Hiroshi Fujishima: Influência estatística
Relatório de execução
| Concept | World rank |
|---|---|
| scores hyperemia | #1 |
| atopic keratoconjunctivitis akc | #1 |
| antagonists child conjunctivitis | #1 |
| production tranilast | #1 |
| clinical signs akc | #1 |
| compared fluorometholone | #1 |
| eyebon | #1 |
| eyewash solution bak | #1 |
| allergic conjunctivitis efficacy | #1 |
| artificial tears positive | #1 |
| rsv conjunctival | #1 |
| corneal epithelium disorders | #1 |
| experience 01 | #1 |
| primary human conjunctival | #1 |
| initiation tacrolimus treatment | #1 |
| therapy levocabastine | #1 |
| tacrolimus ophthalmic solution | #1 |
| rapid ophthalmic | #1 |
| levocabastine artificial | #1 |
| conjunctivitis aims | #1 |
| levocabastine artificial tears | #1 |
| eyewash solutions bak | #1 |
| akc | #1 |
| conclusions objective assessments | #1 |
| eye itching | #1 |
| keratoconjunctivitis background | #1 |
| dscg bf | #1 |
| action child conjunctivitis | #1 |
| fml administered | #1 |
| cedrus conjunctivitis | #1 |
| commercial eyewash | #1 |
| conjunctivitis enrolled | #1 |
| pge2 human conjunctival | #1 |
| akc compared | #1 |
| fml dscg | #1 |
| bf fml | #1 |
| dscg 005 | #1 |
| suppressing pge2 production | #1 |
| commercial washing solution | #1 |
| severity objective signs | #1 |
| il4 tranilast | #1 |
| diseases tear | #1 |
| il4 tear | #1 |
| exacerbation vkc | #1 |
| akc vernal | #1 |
| capilia adeno eye | #1 |
| ketotifen fumarate dexamethasone | #1 |
| instillation bromfenac | #1 |
| test capilia | #1 |
| improvement combinedtreatment | #1 |
| eye allerwatch | #1 |
| tranilast dexamethasone | #1 |
| cases severe conjunctivitis | #1 |
| solution allergic | #1 |
| satisfaction suspensions | #1 |
| postoperative conjunctivitis | #1 |
| fourgraded severity | #1 |
| adverse events scores | #1 |
| prostaglandin tears | #1 |
| include conjunctival | #1 |
| positivity rate allerwatch | #1 |
| drop levocabastine | #1 |
| akc treatment | #1 |
| conjunctival cedar | #1 |
| dha il4 | #1 |
| release inhibitor purpose | #1 |
| bromfenac sodium | #1 |
| vkc april | #1 |
| hundredandseventy eyes | #1 |
| tears allergic | #1 |
| allergic conjunctivitis drop | #1 |
| rate allerwatch | #1 |
| bromobenzenes conjunctivitis | #1 |
| efficacy bromfenac sodium | #1 |
| sodium allergic | #1 |
| allergic postoperative | #1 |
| tacrolimus ophthalmic | #1 |
| adeno eye | #1 |
| cd3 cd4bearing cells | #1 |
| severe akc | #1 |
| allergenmediated conjunctivitis | #1 |
| tacrolimus ophthalmic suspension | #1 |
| akc tear | #1 |
| sodium bf | #1 |
| akc allergic | #1 |
| commercial eyewash solutions | #1 |
| il4 causing | #1 |
| cytokinestimulation pharmacologic intervention | #1 |
| higher capilia | #1 |
| patients capilia | #1 |
| tacrolimus eye drops | #1 |
| eye fml | #1 |
| pcr eotaxin1 | #1 |
| production ketotifen fumarate | #1 |
| allerwatch tests | #1 |
| 01 tacrolimus eye | #1 |
| instillation symptoms | #1 |
| conjunctivitis japanese | #1 |
| keratoconjunctivitis akc | #1 |
| fml 002 | #1 |
| patients severe conjunctivitis | #1 |
| tacrolimus eye | #1 |
| bromfenac sodium treatment | #1 |
| allergens levocabastine | #1 |
| severe binocular conjunctivitis | #1 |
| 12 patients akc | #1 |
| systemic control pain | #1 |
| inhibition eotaxin1 | #1 |
| eye wash | #1 |
| tacrolimus tears | #1 |
| solution ocular | #1 |
| tnfalpha tranilast dexamethasone | #1 |
| objective findings conclusions | #1 |
| ige allerwatch | #1 |
| washing allergens | #1 |
| suspension treating | #1 |
| tears allergic patients | #1 |
| radioimmunoassay il4 | #1 |
| eyewash | #1 |
| allerwatch higher | #1 |
| patients atopic keratoconjunctivitis | #1 |
| stat6results | #1 |
| conjunctivitis scleritis episcleritis | #1 |
| conjunctivitis helper | #1 |
| samples allergic conjunctivitis | #1 |
| ded anti | #1 |
| initiating tacrolimus | #1 |
| hyperemia pain | #1 |
| efficacy fml | #1 |
| bak epithelium | #1 |
| selected fml | #1 |
| eye surface years | #1 |
| iop akc | #1 |
| itchy sensation | #1 |
| akc vkc | #1 |
| vkc cases | #1 |
| production conjunctival fibroblasts | #1 |
| severe conjunctivitis eyes | #1 |
| cox2 conjunctival | #1 |
| treatment vernal keratoconjunctivitis | #1 |
| 01 ophthalmic solution | #1 |
| eyebon eye | #1 |
| keratocytes tnfα | #1 |
| bak epithelium disorders | #1 |
| tacrolimus eye drop | #1 |
| fumarate dexamethasone | #1 |
| fluorometholone 002 | #1 |
| patients akc | #1 |
| dscg symptoms | #1 |
| allergic conjunctivitis | #1 |
| concomitant bf | #1 |
| tranilast eotaxin1 | #1 |
| 10 objective signs | #1 |
| allergic enzyme | #1 |
| characterized conjunctival | #1 |
| ocular allergic diseases | #1 |
| incubated interleukin | #1 |
| dscg fml | #1 |
| tears conjunctival fibroblasts | #1 |
| bf concomitantly | #1 |
| epithelium disorders | #1 |
| talymus | #1 |
| patients allergic conjunctivitis | #1 |
| vkc conclusions | #1 |
| signs palpebral | #1 |
| immunocytochemical study rtpcr | #1 |
| higher akc | #1 |
| keratoconjunctivitis male | #1 |
| allergic corneal | #1 |
| conjunctival fibroblasts | #1 |
| adenovirus capilia | #1 |
| atopic keratoconjunctivitis | #1 |
| keratoconjunctivitis vernal | #1 |
| conjunctivitis including | #1 |
| conjunctivitis conjunctival | #1 |
| epithelial pge2 | #1 |
| conjunctivitis seasonal | #1 |
| scleritis tacrolimus | #1 |
| vkc akc | #1 |
| akc administration | #1 |
| tranilast production | #1 |
| allerwatch positivity rate | #1 |
| child conjunctivitis | #1 |
| eotaxin1 production | #1 |
| conjunctivitis concomitantly | #1 |
| capilia adeno | #1 |
| itching levocabastine | #1 |
| akc patients | #1 |
| accuracy conjunctivitis | #1 |
| subjective ocular symptoms | #1 |
| selective chemotactic effects | #1 |
| eotaxin conjunctival fibroblasts | #1 |
| 0001 allerwatch | #1 |
| binocular conjunctivitis | #1 |
| nsaids systemic control | #1 |
| akc methods | #1 |
| diagnostic accuracy conjunctivitis | #1 |
| dha western blotting | #1 |
| conjunctivitis treated | #1 |
| allergic docosahexaenoic | #1 |
| allerwatch diagnostic accuracy | #1 |
| eyewash solution | #1 |
| fml patients | #1 |
| 3 months signs | #1 |
| adult cedrus conjunctivitis | #1 |
| sodium ophthalmic solution | #1 |
| tacrolimus eye treatment | #1 |
| drops elicited | #1 |
| eyewash solutions | #1 |
| conjunctival fibroblasts production | #1 |
| allergic tranilast | #1 |
| bromfenac sodium bf | #1 |
| treatment shield ulcer | #2 |
| steroid metaregression | #2 |
| eyelid atopic | #2 |
| production specular | #2 |
| concomitantly abovementioned | #2 |
| oral ari | #2 |
| csa akc | #2 |
| vkc atopic keratoconjunctivitis | #2 |
| edema corneal damage | #2 |
| sodium ophthalmic | #2 |
| papillary excision | #2 |
| 1 month tacrolimus | #2 |
| corneal damage patients | #2 |
| atopic blepharitis | #2 |
| resolution thermography | #2 |
| tear film layer | #2 |
| cytodiagnosis dermatitis | #2 |
| suspension talymus | #2 |
| limbal swelling | #2 |
| drops conjunctival | #2 |
| placebo noninferiority | #2 |
| epinastine superiority | #2 |
| oral ari administration | #2 |
| rhodanine rose | #2 |
| sem575 | #2 |
| administration specular | #2 |
| patients shield | #2 |
| tacrolimus detection limit | #2 |
| treatment tear | #2 |
| japan topical tacrolimus | #2 |
| papillae limbus | #2 |
| akc treated | #2 |
| epitheliopathy corneal | #2 |
| correlation neutrophils | #2 |
| keratoconjunctivitis corneal | #2 |
| cornea grading | #2 |
| giant papillae formation | #2 |
| ketotifen dexamethasone | #2 |
| study designopen cohort | #2 |
| premedication combined | #2 |
| lid skin | #2 |
| including akc | #2 |
| diathesis subjective | #2 |
| noninferiority olopatadine | #2 |
| lesions allergic | #2 |
| methods thirtysix patients | #2 |
| plaques 791 | #2 |
| scores tacrolimus | #2 |
| epitheliopathy shield | #2 |
| allergic endophthalmitis | #2 |
| allergic conjunctivitis levocabastine | #2 |
| simple papillary resection | #2 |
| tacrolimus iop | #2 |
| tacrolimus detection | #2 |
| ocular surface mucin | #2 |
| ecp severity markers | #2 |
| hyperemia lacrimation | #2 |
| dermatitis remission | #2 |
| epitheliopathy patients | #2 |
| papilla accompanied | #2 |
| epinastine 15 minutes | #2 |
| baseline papillae | #2 |
| score adjustments | #2 |
| corneal temperature patients | #2 |
| air pollutants prevalence | #2 |
| signs blood concentration | #2 |
| representative subjective | #2 |
| oral ari ono2235 | #2 |
| 2helper cell | #2 |
| 001 brush | #2 |
| tacrolimus 12 weeks | #2 |
| patients tacrolimus eye | #2 |
| total clinical signs | #2 |
| conjunctiva conjunctivitis allergic | #2 |
| drop concomitantly | #2 |
| tarsal brush | #2 |
| akc 10 | #2 |
| giant papillary formation | #2 |
| asthma heart diseases | #2 |
| adjustments epitheliopathy score | #2 |
| talymus akc | #2 |
| recurrence corneal lesions | #2 |
| elasticity eyelid | #2 |
| allergic diagnosis | #2 |
| sem575 clinical | #2 |
| conjunctivitis proliferative | #2 |
| lactoferrin 01 | #2 |
| corneal epithelial signs | #2 |
| treatment total signs | #2 |
| adjuvant fluorometholone | #2 |
| adjuvant betamethasone | #2 |
| brush cytology patients | #2 |
| adjustments epitheliopathy | #2 |
| epinastine ophthalmic solution | #2 |
| akc levels | #2 |
| akc adult | #2 |
| akc 1 | #2 |
| improvement vital staining | #2 |
| eyelid skin elasticity | #2 |
| corneal damage height | #2 |
| bovine placebo | #2 |
| formation palpebral | #2 |
| tacrolimus topical | #2 |
| treatment atopic blepharitis | #2 |
| benzophenones bromobenzenes | #2 |
| patients corneal ulcers | #2 |
| elevation tacrolimus | #2 |
| simple resection regrowth | #2 |
| mucous discharge severity | #2 |
| corneal epitheliopathy score | #2 |
| fluorescein conjunctival injection | #2 |
| conjunctival injection reduction | #2 |
| administered elf bovine | #2 |
| metaregression analysis glaucoma | #2 |
| evaluate superiority | #2 |
| test papillae | #2 |
| skin elasticity patients | #2 |
| eyewash 005 | #2 |
| conjunctiva bulbar | #2 |
| severity corneal lesions | #2 |
| elasticity severity | #2 |
| akc aureus | #2 |
| eosinophils corneal damage | #2 |
| post cataract surgery | #2 |
| bromfenac sodium bromfenac | #2 |
| 95 adjuvant betamethasone | #2 |
| conjunctiva atopic | #2 |
| treated bromfenac | #2 |
| papillae severe | #2 |
| betamethasone glaucoma | #2 |
| total signs symptoms | #2 |
| dryness scores | #2 |
| corneal findings | #2 |
| unpaired ttest talymus | #2 |
| recurrence corneal complications | #2 |
| 18 akc | #2 |
| blepharitis ceramides | #2 |
| reported eotaxin | #2 |
| environmental studies prevalence | #2 |
| excision cobblestone | #2 |
| accompanied subjective | #2 |
| extents corneal | #2 |
| efficacy severe akc | #2 |
| tear ige correlation | #2 |
| muc16 immunohistochemistry | #2 |
| conjunctiva papillary | #2 |
| normal blinking patients | #2 |
| swelling folliculosis | #2 |
| tacrolimus tonometry | #2 |
| tears thiazolidines | #2 |
| diagnosis ensured | #2 |
| japan akc | #2 |
| aided papillary | #2 |
| corneal recurrences | #2 |
| aureussecreted enterotoxins | #2 |
| correlation fluorescein | #2 |
| pollutants prevalence | #2 |
| cutometer sem575 | #2 |
| sodium bromfenac | #2 |
| japan topical | #2 |
| conclusions bromfenac | #2 |
| drop steroid | #2 |
| detected akc | #2 |
| mucin analyzed | #2 |
| 062 tear | #2 |
| ceramide gel application | #2 |
| complain foreign | #2 |
| solutions japan | #2 |
| bovine entericcoated lactoferrin | #2 |
| folliculosis papillae | #2 |
| atopic diagnostic techniques | #2 |
| refractory allergic | #2 |
| formation akc | #2 |
| steroids epitheliopathy | #2 |
| eyes betamethasone | #2 |
| bromfenac ophthalmic solution | #2 |
| papillae mucous discharge | #2 |
| eyes 824 | #2 |
| patients shield ulcers | #2 |
| sac healthy | #2 |
| mmc aided | #2 |
| ecp levels akc | #2 |
| defined conjunctival | #2 |
| based papillae | #2 |
| corneal ulcers patients | #2 |
| solution epinastine | #2 |
| epitheliopathy steroids | #2 |
| conjunctivitis purpose | #2 |
| conventional antiallergic drugs | #2 |
| drops hyperemia | #2 |
| tacrolimus lessen | #2 |
| papillae preventing | #2 |
| serum allergic parameters | #2 |
| akc 6 | #2 |
| tacrolimus published data | #2 |
| decrease corneal temperature | #2 |
| papillary formation | #2 |
| deqs tear | #2 |
| effects topical tacrolimus | #2 |
| severity corneal damage | #2 |
| cedrus conjunctiva | #2 |
| severity corneal complications | #2 |
| patients severe akc | #2 |
| female humans akc | #2 |
| effects tacrolimus | #2 |
| ari ocular | #2 |
| shield ulcers patients | #2 |
| regrowth papillae | #2 |
| tears akc | #2 |
| allergy accompanied | #2 |
| conjunctivitis epitheliopathy | #2 |
| control subjects eyes | #2 |
| factor vkc | #2 |
| administered elf | #2 |
| immunoregulatory effects study | #2 |
| scores papillary | #2 |
| allergic conjunctivitis ige | #2 |
| nonwash | #2 |
| olopatadine visit | #2 |
| conjunctival corneal cells | #2 |
| conjunctivitis representative | #2 |
| conjunctivitis condition | #2 |
| inflammatory child child | #2 |
| akc allergic diagnosis | #2 |
| signs decreased | #2 |
| endpoint itching scale | #2 |
| adjuvant fluorometholone 95 | #2 |
| topical antiallergic agents | #2 |
| largescale study protocol | #2 |
| ensured proving | #2 |
| period rhodanine | #2 |
| treatment ecp concentrations | #2 |
| topical tacrolimus combination | #2 |
| edema height | #2 |
| tacrolimus shield | #2 |
| conjunctival findings severity | #2 |
| allergic conjunctivitis akc | #2 |
| bromfenac effective | #2 |
| conjunctivitis adolescent | #2 |
| akc adolescent | #2 |
| conjunctivitis 10 | #2 |
| neutrophils brush | #2 |
| eyelid atopic dermatitis | #2 |
| nonpreserved eyewash solution | #2 |
| lacrimation objective | #2 |
| pge2 tears | #2 |
| epitheliopathy score | #2 |
| corneal epitheliopathy | #2 |
| diabetic patients ono2235 | #2 |
| keratoconjunctivitis age | #2 |
| objective signs baseline | #2 |
| cac test | #2 |
| lower conjunctival sacs | #2 |
| neutrophils corneal damage | #2 |
| improvement corneal fluorescein | #2 |
| ophthalmic nsaid | #2 |
| akc 10 eyes | #2 |
| tacrolimus 1 month | #2 |
| akc sac patients | #2 |
| cobblestonelike papillae | #2 |
| correlation eosinophils | #2 |
| eyelid elasticity | #2 |
| conjunctivitis retrospective | #2 |
| olopatadine ocular | #2 |
| seasonal allergic conjunctivitis | #2 |
| regrowth 7 eyes | #2 |
| ulcer complain | #2 |
| height papillae | #2 |
| disease antiallergic | #2 |
| akc patients correlation | #2 |
| month eyewash | #2 |
| prevalence akc | #2 |
| selected bf | #2 |
| corneal lesions | #2 |
| corneal lesions regrowth | #2 |
| oral aldose | #2 |
| severe allergic conjunctivitis | #2 |
| corneal complications height | #2 |
| vkc japan | #2 |
| brush cytology samples | #2 |
| lessen steroid | #2 |
| severity eyelid | #2 |
| drops refractory | #2 |
| superiority epinastine | #2 |
| sem575 quantitatively | #2 |
| score topical | #2 |
| proliferative called | #2 |
| excision cobblestonelike papillae | #2 |
| vkc 5 | #2 |
| iop topical steroids | #2 |
| akc young adult | #2 |
| papillae akc | #2 |
| conjunctival injection edema | #2 |
| suspension lactoferrin | #2 |
| mmc 7 eyes | #2 |
| epitheliopathy refractory | #2 |
| olopatadine cedar | #2 |
| periostin comorbidities | #3 |
| commercial washing | #3 |
| diabetic corneal disease | #3 |
| temperature evaluate | #3 |
| periostin akc | #3 |
| prophylaxis conjunctival | #3 |
| fluorescein glycyrrhizic | #3 |
| measurements schirmer | #3 |
| superficial cells conjunctiva | #3 |
| scale tmh | #3 |
| icecold eye mask | #3 |
| cell metry | #3 |
| adedry eye | #3 |
| par2 cultured | #3 |
| elisa histamine | #3 |
| dramatic healing | #3 |
| treatment vernal | #3 |
| induced inflammation lenses | #3 |
| traumatic swelling | #3 |
| drops treat | #3 |
| lower muc5ac | #3 |
| conjunctivitis pm25 | #3 |
| oct tmh | #3 |
| dfna eye | #3 |
| histamine cedar pollen | #3 |
| increased comfort | #3 |
| papillae upper | #3 |
| eyes akc | #3 |
| aged biological dressings | #3 |
| epithelium adverse | #3 |
| formation vernal | #3 |
| vkc papillae | #3 |
| mmc authors | #3 |
| akc periostin | #3 |
| akc alterations | #3 |
| healing allergic | #3 |
| akc confocal microscopy | #3 |
| techniques conjunctivitis | #3 |
| cases vkc | #3 |
| hydrochloride 01 | #3 |
| evaluate tear | #3 |
| severe allergic patients | #3 |
| uncontrollable glaucoma trabeculectomy | #3 |
| benzamidine par2 | #3 |
| akc dyes humans | #3 |
| child conjunctiva | #3 |
| techniques tears | #3 |
| eyes vkc | #3 |
| healing dramatic healing | #3 |
| tear periostin biomarker | #3 |
| nbs normal eyes | #3 |
| underwent staining | #3 |
| operation eye | #3 |
| differences dfna | #3 |
| flare metry | #3 |
| sde controls | #3 |
| par2 benzamidines blotting | #3 |
| vkc relevant factor | #3 |
| dry eye eye | #3 |
| thermography evaluate | #3 |
| ophthalmic solution placebo | #3 |
| vkc eyes | #3 |
| portable recordable | #3 |
| inflammation mmc | #3 |
| 111 177 | #3 |
| membrane uncontrollable | #3 |
| akc comorbidities | #3 |
| conjunctivitis benzamidines | #3 |
| erosions refractory | #3 |
| akc rose bengal | #3 |
| decline corneal | #3 |
| allergic postsurgical | #3 |
| sensitivity tear | #3 |
| akc higher | #3 |
| higher muc1 eyes | #3 |
| periostin topical | #3 |
| production conjunctival | #3 |
| vkc cell | #3 |
| 12 akc | #3 |
| mmc excision | #3 |
| pollen postoperative | #3 |
| insufficient tear | #3 |
| vkc fibronectin | #3 |
| phenomena tacrolimus | #3 |
| allergic conjunctivitis aged | #3 |
| akc serum periostin | #3 |
| surgery dfna | #3 |
| histamine specimens | #3 |
| outpatient attendance july | #3 |
| 01 bromfenac | #3 |
| rtpcr par2 | #3 |
| ulcers eyes | #3 |
| 3 sjögrens syndrome | #3 |
| ebv ade | #3 |
| cultured tryptase | #3 |
| histamine cedar | #3 |
| relevant factor exacerbation | #3 |
| 21 akc | #3 |
| tryptase conjunctiva | #3 |
| pm25 outpatient attendance | #3 |
| uncontrollable glaucoma | #3 |
| cases vernal | #3 |
| conjunctivitis lymphocytes | #3 |
| metry dfna | #3 |
| vkc differences | #3 |
| fibronectin normal controls | #3 |
| vkc exacerbation | #3 |
| tryptase increases | #3 |
| study cutometer | #3 |
| existence par2 mrna | #3 |
| central corneal temperature | #3 |
| akc higher muc1 | #3 |
| treatment skin elasticity | #3 |
| proving type | #3 |
| patients tmh measurements | #3 |
| 005 ophthalmic solution | #3 |
| diclofenac epithelium | #3 |
| vkc 5 eyes | #3 |
| aged elisa | #3 |
| improvement squamous metaplasia | #3 |
| interleukin4 histamine | #3 |
| normal controls collagens | #3 |
| nonpreserved artificial tears | #3 |
| conjunctival corneal | #3 |
| akc persistent | #3 |
| papillary resection | #3 |
| mmcaided papillary resection | #3 |
| severe allergy patients | #3 |
| ulcer akc | #3 |
| treatment atopic keratoconjunctivitis | #3 |
| allerwatch | #3 |
| sdedry eye | #3 |
| strip meniscometry testing | #3 |
| rose bengal akc | #3 |
| cytology impression | #3 |
| drop selected | #3 |
| giant papilla | #3 |
| 22 eyes 100 | #3 |
| cholinergic treatment response | #3 |
| pm25 allergic | #3 |
| fibronectin vkc | #3 |
| allergic corneal ulcer | #3 |
| dibenzoxepins female | #3 |
| postsurgical conjunctivitis | #3 |
| muc1 brush cytology | #3 |
| laser cellflaremetry | #3 |
| lamp device | #3 |
| ophthalmic solution nsaid | #3 |
| laser flarecellmetry | #3 |
| conjunctival fibroblasts tryptase | #3 |
| superior keratoconjunctiva | #3 |
| eye washing | #3 |
| papillae morphometric | #3 |
| reaction conjunctiva | #3 |
| samples correlate | #3 |
| vkc long | #3 |
| akc confocal | #3 |
| patching case | #3 |
| corneal complications1 | #3 |
| ocular surface diabetes | #3 |
| scored global | #3 |
| cornea atopic | #3 |
| fibers lnfs | #3 |
| antiallergic eye drop | #3 |
| histamine conjunctival cells | #3 |
| signs remission | #3 |
| tear periostin comorbidities | #3 |
| corneal epithelial structure | #3 |
| insensible administration insensible | #3 |
| tear il13 | #3 |
| immunosuppressive eye | #3 |
| patching patient | #3 |
| infrared radiation thermography | #3 |
| akc biomarkers | #3 |
| papillary regrowth | #3 |
| allergic corneal diseases | #3 |
| formation vkc | #3 |
| treatment oral pilocarpine | #3 |
| conjunctivitis allergic | #3 |
| 1 month initiation | #3 |
| conjunctivitis negative | #3 |
| diseases acds | #3 |
| dfna control | #3 |
| protein conjunctival fibroblasts | #3 |
| tissue remodeling exacerbation | #3 |
| permeability postoperatively | #3 |
| patients pilocarpine tablets | #3 |
| conjunctival fibroblasts rtpcr | #3 |
| local tear deficiency | #3 |
| prospectively diclofenac | #3 |
| keratoconjunctivitis vkc | #3 |
| corneal ulceration role | #3 |
| autumnal pollen | #3 |
| akc tear periostin | #3 |
| 005 mmc | #3 |
| 5ac brush | #3 |
| eyes allergic | #3 |
| pretreatment docosahexaenoic acid | #3 |
| cells brush cytology | #3 |
| outpatient visits july | #3 |
| titers ade | #3 |
| nuclei vkc | #3 |
| ari corneal | #3 |
| efficacy bromfenac | #3 |
| vivo corneal akc | #3 |
| eosinophils corneal | #3 |
| tears treatment | #3 |
| pilocarpine visante | #3 |
| tears adolescent | #3 |
| antibody titers ade | #3 |
| eyes control subjects | #3 |
| insufficient tear supply | #3 |
| technique uncontrollable | #3 |
| cell flare count | #3 |
| 5ac mrna | #3 |
| weekly average values | #3 |
| technique 2 eyes | #3 |
| sligkv examined | #3 |
| akc atopic dermatitis | #3 |
| 12 akc patients | #3 |
| underwent periodic | #3 |
| antieaigg | #3 |
| 01 ophthalmic | #3 |
| dfna eye dfna | #3 |
| allergic patients conjunctivitis | #3 |
| ssdry | #3 |
| eye cooling | #3 |
| epinastine placebo | #3 |
| conjunctival disease | #3 |
| alterations tear | #3 |
| macroerosions | #3 |
| 13 eyes 69 | #3 |
| glaucoma amniotic | #3 |
| tmh measurement | #3 |
| tear periostin patients | #3 |
| july pm25 | #3 |
| association outpatient attendance | #3 |
| dscg administration | #3 |
| aureus akc patients | #3 |
| corneal akc | #3 |
| vkc levels | #3 |
| cooling cataract | #3 |
| diclofenac eye drops | #3 |
| akc eyes | #3 |
| conjunctiva conjunctivitis | #3 |
| histamine superficial cells | #3 |
| vkc sac | #3 |
| nbs subbasal | #3 |
| ulcer persistent | #3 |
| oct graticule | #3 |
| keratoconjunctivitis leupeptins | #3 |
| lnfs nbs | #3 |
| 005 collagens | #3 |
| dfna diclofenac epithelium | #3 |
| interleukin4 tacrolimus | #3 |
| il1beta th2 cytokines | #3 |
| solutions prospective | #3 |
| ecp severity | #3 |
| tear periostin | #3 |
| conjunctiva allergic | #3 |
| 21 akc patients | #3 |
| pollen august | #3 |
| allergic cornea | #3 |
| hyperemia allergic | #3 |
| outpatient visits august | #3 |
| lacrimal punctal occlusion | #3 |
| injections keratoconjunctivitis | #3 |
| superior limbic portion | #3 |
| il1beta th2 | #3 |
| ulcers plaques | #3 |
| fluorescein scale | #3 |
| healed amniotic | #3 |
| 5 eyes akc | #3 |
| topical cyclosporine 01 | #3 |
| treatment strip meniscometry | #3 |
| existence par2 | #3 |
| insignificant epithelial disease | #4 |
| tryptase dose | #4 |
| akc sac | #4 |
| goblet cell muc5ac | #4 |
| rsv conjunctiva | #4 |
| p0001 brush | #4 |
| aged rose | #4 |
| july pollen | #4 |
| interferometry 2 | #4 |
| patients severe vkc | #4 |
| eosinophil toxic activity | #4 |
| eotaxin1 rantes | #4 |
| moisture checker | #4 |
| cytology goblet | #4 |
| grade dry eye | #4 |
| metaregression analysis effects | #4 |
| 4 chemokines stimulation | #4 |
| corneal safety | #4 |
| sac control eyes | #4 |
| thinoptx acrysof | #4 |
| special brush | #4 |
| akc crth2 | #4 |
| 10 seconds temperature | #4 |
| staining muc16 | #4 |
| surface conjunctival | #4 |
| levocabastine h1 | #4 |
| disease akc | #4 |
| 020 013 | #4 |
| conjunctivitis vkc | #4 |
| lesions regrowth | #4 |
| alterations atopic | #4 |
| allergic cytological | #4 |
| eosinophils receptor crth2 | #4 |
| eyes thinoptx | #4 |
| epithelial disease patients | #4 |
| par2 mrna protein | #4 |
| tear function test | #4 |
| correlation outpatient | #4 |
| pgd2dependent migration eosinophils | #4 |
| keratoconjunctivitis lacrimal | #4 |
| interleukin2 tears | #4 |
| highrisk glaucoma patients | #4 |
| atopic dermatitis remission | #4 |
| deqs scores | #4 |
| akcaffected patients | #4 |
| asian dust extract | #4 |
| tears 10 patients | #4 |
| eye sjögrens syndrome | #4 |
| patient eyes fluorescein | #4 |
| studied corneal | #4 |
| eyes epithelial disease | #4 |
| corneal ulcers eyes | #4 |
| eye operation | #4 |
| completely severe | #4 |
| eyes video | #4 |
| sterilized asian | #4 |
| lower tear function | #4 |
| genes conjunctival | #4 |
| tacrolimus conclusions | #4 |
| fibroblasts primary sources | #4 |
| chemokine genes fibroblasts | #4 |
| exponential equation inclination | #4 |
| diseases portable | #4 |
| defensins conjunctivitis | #4 |
| tomography tear | #4 |
| interferometry lipids | #4 |
| placebo ophthalmic | #4 |
| immunologic receptors akc | #4 |
| membrane patching | #4 |
| histamine h1 antagonist | #4 |
| ded 1 | #4 |
| eyes sac | #4 |
| akc chemotaxis | #4 |
| implantation rollable | #4 |
| steroids iop | #4 |
| atopic ocular allergies | #4 |
| ulcers control subjects | #4 |
| topical oral steroids | #4 |
| eyes corneal ulcers | #4 |
| microscope evaluating | #4 |
| samples immunocytochemical | #4 |
| staining muc | #4 |
| cultured conjunctival | #4 |
| eye wash solution | #4 |
| ophthalmologists eye drops | #4 |
| steroids fluorometholone | #4 |
| p0001 impression | #4 |
| thinoptx lens | #4 |
| papillae normal | #4 |
| fungi epidemiologic studies | #4 |
| temperature corneal | #4 |
| thinoptx | #4 |
| 33 chemokines | #4 |
| sac grade | #4 |
| inflammation akc | #4 |
| samples allergic | #4 |
| portable slit | #4 |
| primary sources chemokines | #4 |
| proteinchip array elisa | #4 |
| patient atopic keratoconjunctivitis | #4 |
| untreated asian dust | #4 |
| vkc messenger reverse | #4 |
| pgd2 normal volunteers | #4 |
| include ocular | #4 |
| akc healthy individuals | #4 |
| adolescent betamethasone | #4 |
| epithelial muc | #4 |
| rsv conjunctival epithelium | #4 |
| 3004 respondents | #4 |
| allergic patients elisa | #4 |
| sensitization asian dust | #4 |
| tnfalpha30ng | #4 |
| controls brush cytology | #4 |
| 2010 allergic | #4 |
| oedema papillary | #4 |
| conjunctiva differences | #4 |
| 2 4 alterations | #4 |
| vkc male receptors | #4 |
| vkc conjunctiva conjunctivitis | #4 |
| papillae giant | #4 |
| eyes ulcers | #4 |
| months papillary | #4 |
| formation conjunctivitis | #4 |
| acds conventional | #4 |
| rejection limbal | #4 |
| epinastine hydrochloride | #4 |
| atopic ocular | #4 |
| dust wheal | #4 |
| eyes akc patients | #4 |
| drop artificial tears | #4 |
| conjunctivitis levels | #4 |
| muc1 2 | #4 |
| bromfenac ophthalmic | #4 |
| epithelial muc16 | #4 |
| thermometer 20 | #4 |
| corneal sensitivity measurement | #4 |
| blinding purpose | #4 |
| surface muc5ac | #4 |
| muc5ac brush | #4 |
| controls interferometry grade | #4 |
| recordable slit | #4 |
| pcr epithelial | #4 |
| limbal grafts | #4 |
| interferometry grade | #4 |
| conjunctival proliferative | #4 |
| 0001 brush | #4 |
| acds ophthalmologists | #4 |
| allergies blinding | #4 |
| lower tear clearance | #4 |
| pathogenesis noninfectious | #4 |
| cytometry mild cases | #4 |
| controls interferometry | #4 |
| allergic conjunctival disease | #4 |
| allergic fibroblasts | #4 |
| akc rtpcr | #4 |
| persistent 6 | #4 |
| allergic conjunctival | #4 |
| akc pgd2dependent migration | #4 |
| defensins greater | #4 |
| patients epithelial disease | #4 |
| ocular allergic disease | #4 |
| tears patients | #4 |
| conjunctivitis methods | #4 |
| levocabastine ophthalmic | #4 |
| pgd2dependent migration | #4 |
| corneal temperature eye | #4 |
| stimulation chemokine expression | #4 |
| allergic conjunctival diseases | #4 |
| healthy individuals rtpcr | #4 |
| implantation thinoptx | #4 |
| allergic conjunctivitis prostaglandin | #4 |
| level conjunctiva | #4 |
| underwent corneal | #4 |
| samples histocytological | #4 |
| conjunctiva density | #4 |
| specimens underwent | #4 |
| akc healthy | #4 |
| muc5ac mrna expression | #4 |
| wilcoxon signed test | #4 |
| excision papillary | #4 |
| cells lnfs | #4 |
| il4 tears | #4 |
| ulcers mucin | #4 |
| 061 028 degree | #4 |
| interferometry controls | #4 |
| sterilized asian dust | #4 |
| corneal temperature blink | #4 |
| bengal sensation | #4 |
| topical 01 tacrolimus | #4 |
| sensation tears | #4 |
| performed tears | #4 |
| ocular surface epithelial | #4 |
| simple resection | #4 |
| infected conjunctival | #4 |
| weeks vital | #4 |
| crth2 akc | #4 |
| 34 15 seconds | #4 |
| subjects muc5ac | #4 |
| ophthalmologists evaluated | #4 |
| ige conjunctival | #4 |
| epithelial cells rsv | #4 |
| vmr 3 months | #4 |
| ulcers atopic | #4 |
| mucins tears mucin | #4 |
| atopic vernal | #4 |
| compared vkc | #4 |
| crth2 peripheral | #4 |
| keratoconjunctivitis purpose | #4 |
| tear temperature | #4 |
| mucin mucins tears | #4 |
| metaplasia reduction | #4 |
| folliculosis | #4 |
| 18 akc patients | #4 |
| muc5ac brush cytology | #4 |
| vkc normal controls | #4 |
| individuals pgd2 | #4 |
| tear function patients | #4 |
| epithelial disease eyes | #4 |
| noninfectious necrotizing | #4 |
| cornea grading scale | #4 |
| severe vkc patients | #4 |
| hypersensitivity mucin | #4 |
| akc crth2 expression | #4 |
| acuity akc | #4 |
| muc16 muc5ac alterations | #4 |
| mucins 1 | #4 |
| scores conjunctival | #4 |
| akc immunologic receptors | #4 |
| muc16 goblet | #4 |
| trantas | #4 |
| assay pgd2 | #4 |
| diameter allergen | #4 |
| ari ono2235 | #4 |
| conjunctival papillary | #4 |
| cases sufficient examination | #4 |
| muc5ac alterations | #4 |
| rsv allergic reaction | #4 |
| allergic rhinoconjunctivitis allergic | #4 |
| conjunctivitis ige | #4 |
| corneal ulcers muc5ac | #4 |
| vkc 4 | #4 |
| photophobia diagnosis | #4 |
| allergic conjunctivitis rsv | #4 |
| bromfenac eye drops | #4 |
| giemsas staining | #4 |
| cytometry mild | #4 |
| staining ocular | #4 |
| rsv conjunctiva conjunctivitis | #4 |
| corneal sensitivity measurements | #4 |
| dscg day | #4 |
| chemotaxis conjunctiva | #4 |
| patients topical cyclosporine | #4 |
| hydrochloride ophthalmic | #4 |
| conjunctiva allergic conjunctivitis | #4 |
| solutions piperidines | #4 |
| treatment vmr values | #4 |
| greater 3 grade | #4 |
| treatment vmr | #4 |
| greater concentrations tears | #4 |
| cell muc5ac | #4 |
| clinical conjunctival | #4 |
| male ophthalmic | #4 |
| atopic keratoconjunctivitis purpose | #4 |
| fva treatment | #4 |
| severe ocular allergies | #4 |
| thermography anterior | #4 |
| erosion shield | #4 |
| insignificant epithelial | #4 |
| eyes insignificant | #4 |
| tears pathogenesis | #4 |
| allergic epidemiologic studies | #4 |
| sio2 20 | #4 |
| thinoptx intraocular | #4 |
| epithelial pge2 production | #4 |
| conventional portable | #4 |
| rose bengal scores | #4 |
| tablets tears | #4 |
| status confocal | #5 |
| months amniotic | #5 |
| lipid oxidation hel | #5 |
| akc normal subjects | #5 |
| hel akc | #5 |
| conjunctiva mmc | #5 |
| allergic drug therapy | #5 |
| tnfα costimulation | #5 |
| severe conjunctivitis | #5 |
| allergic keratopathy | #5 |
| 0001 strip | #5 |
| regulation allergic cornea | #5 |
| supernatants conjunctival | #5 |
| allergic female | #5 |
| scans akc | #5 |
| oct lower | #5 |
| vkc iop | #5 |
| conjunctiva dermatitis | #5 |
| labeling surface akc | #5 |
| human conjunctival fibroblasts | #5 |
| damage impression | #5 |
| signs akc | #5 |
| eosinophil adherence fibroblasts | #5 |
| age 9 ± | #5 |
| eye circulating | #5 |
| 15 minutes dose | #5 |
| 17 mgd patients | #5 |
| fibroblasts fibroblast damage | #5 |
| bengal suture | #5 |
| disposable eyelid | #5 |
| dryeye symptoms | #5 |
| mitomycin excision | #5 |
| prostaglandin chemotaxis | #5 |
| adolescent conjunctivitis | #5 |
| equipment dry | #5 |
| bromobenzenes cornea | #5 |
| cornea explain | #5 |
| 7 conjunctival | #5 |
| allergic conjunctiva conjunctivitis | #5 |
| 005 schirmer1 | #5 |
| conjunctival lipid | #5 |
| ocular surface disorder | #5 |
| punctal occlusion oct | #5 |
| eosinophils immunologic receptors | #5 |
| treatment dryeye symptoms | #5 |
| akc acinar | #5 |
| tears received | #5 |
| layer mgd | #5 |
| conjunctival allergen | #5 |
| hne ihc | #5 |
| hel ihc | #5 |
| 3 cases followup | #5 |
| measurements strip | #5 |
| 329±57 years | #5 |
| visits august | #5 |
| temperature blink | #5 |
| alterations ocular | #5 |
| case corneal ulcer | #5 |
| simple papillary | #5 |
| mcfg eye | #5 |
| postsurgical inflammation | #5 |
| lesion corneal | #5 |
| hel cytokines | #5 |
| conjunctival inflammatory status | #5 |
| younger age effects | #5 |
| cytokinestimulation | #5 |
| allergic conjunctivitis patients | #5 |
| vcam1 fibroblasts | #5 |
| 20 sio2 | #5 |
| 376±56 years | #5 |
| keratoconjunctivitis objective | #5 |
| stimulated conjunctival | #5 |
| eye warmer | #5 |
| impression cytology samples | #5 |
| akc disease | #5 |
| antifungal mcfg | #5 |
| injection conjunctival | #5 |
| pm25 outpatient | #5 |
| ophthalmic test | #5 |
| fibroblasts eosinophil adherence | #5 |
| crth2 eosinophils | #5 |
| conjunctival confocal microscopy | #5 |
| ocular allergic | #5 |
| 5 females akc | #5 |
| cornea cytodiagnosis | #5 |
| pgd2 normal | #5 |
| corneal involvement | #5 |
| 310±165 years | #5 |
| solution olopatadine | #5 |
| inflammation mitomycin | #5 |
| 20 akc patients | #5 |
| ophthalmic suspension | #5 |
| 01 mcfg | #5 |
| scores expressibility | #5 |
| treatment epinastine | #5 |
| solutions pollen | #5 |
| crth2 prostaglandin receptors | #5 |
| visits july | #5 |
| diclofenac eye | #5 |
| asthenopia dry | #5 |
| accompanying allergic | #5 |
| controls ebv | #5 |
| akc ecp | #5 |
| severe stevensjohnson syndrome | #5 |
| allergic cyclosporine | #5 |
| meniscus punctal | #5 |
| impression brush | #5 |
| keratoconjunctivitis giant | #5 |
| eosinophils activated fibroblasts | #5 |
| wilcoxonmatched pair test | #5 |
| study epinastine | #5 |
| staining muc5ac | #5 |
| staining administration | #5 |
| ulcers controls | #5 |
| thiazolidines administration | #5 |
| trantas dots | #5 |
| vkc atopic | #5 |
| array chemotaxis | #5 |
| ihc conjunctival inflammation | #5 |
| stained conjunctival | #5 |
| pretreatment dha | #5 |
| females akc | #5 |
| damaged eosinophil | #5 |
| histamine superficial | #5 |
| eye warmer treatment | #5 |
| situ nickend regulation | #5 |
| akc patients study | #5 |
| cases tests | #5 |
| inflammatory cells hel | #5 |
| warmer improved | #5 |
| eosinophil adhesion fibroblasts | #5 |
| disposable eyelidwarming device | #5 |
| dryeye symptoms treatment | #5 |
| topical cyclosporine therapy | #5 |
| conjunctivitis pollen | #5 |
| akc hel | #5 |
| ocular anesthesia | #5 |
| month tear | #5 |
| anterior scleritis patients | #5 |
| schiff immunohistochemical | #5 |
| controls inflammatory cells | #5 |
| thinoptx iol | #5 |
| diseases required | #5 |
| treatment tacrolimus ointment | #5 |
| il4 histamine | #5 |
| cells vkc | #5 |
| samples akc | #5 |
| corneal fibroblasts icam1 | #5 |
| schirmer1 test groups | #5 |
| endophthalmitis eosinophils | #5 |
| stainings tear | #5 |
| akc laser | #5 |
| lower atopic | #5 |
| conventional steroid treatment | #5 |
| adhered corneal | #5 |
| treatment shield | #5 |
| ulcer dermatitis | #5 |
| accompanied varying | #5 |
| alpha allergic | #5 |
| severity akc | #5 |
| intraoperative mitomycin excision | #5 |
| conjunctivitis prostaglandin | #5 |
| warmer applied | #5 |
| upper palpebral | #5 |
| anterior fluorometry | #5 |
| local tear | #5 |
| worse akc | #5 |
| disease conjunctivitis | #5 |
| tryptase proliferation | #6 |
| pcr muc5ac | #6 |
| corneal damage | #6 |
| atopic eyelids | #6 |
| regulation benzamidines | #6 |
| allergic conjunctivitis cac | #6 |
| treatment postoperative inflammation | #6 |
| agents interferometry | #6 |
| solution commercial | #6 |
| eosinophils crth2 | #6 |
| cys ocular | #6 |
| testing tear | #6 |
| fva landolt | #6 |
| papillae mucous | #6 |
| scores goblet | #6 |
| ade sde | #6 |
| topical levocabastine | #6 |
| evaporation vital | #6 |
| allergens cedrus | #6 |
| akc vernal keratoconjunctivitis | #6 |
| tear eosinophil | #6 |
| conjunctivitis sac | #6 |
| fluorometholone follow | #6 |
| patients visante | #6 |
| syndrome tablets | #6 |
| dfna | #6 |
| specimens akc | #6 |
| intolerable irritation | #6 |
| tears xerophthalmia | #6 |
| 20 pbs | #6 |
| inflammatory cell densities | #6 |
| allergic diathesis | #6 |
| concomitant eye | #6 |
| akc refractory | #6 |
| upper tarsal conjunctiva | #6 |
| topical cys treatment | #6 |
| tears acinar | #6 |
| female fluorometholone | #6 |
| cgvhd improvements | #6 |
| patients seldi | #6 |
| sde ade | #6 |
| diseases periostin | #6 |
| extract sterilized | #6 |
| rtpcr epithelial cells | #6 |
| density conjunctival | #6 |
| strip meniscometry scores | #6 |
| treatment tacrolimus | #6 |
| tranilast inhibition | #6 |
| samples underwent | #6 |
| pathogenesis ocular | #6 |
| signs scored | #6 |
| functions topical | #6 |
| schirmer1 test values | #6 |
| dermatitis scored | #6 |
| tbut vital | #6 |
| 4 9 genes | #6 |
| topical cys | #6 |
| elevation refractory | #6 |
| grading tear | #6 |
| corneal temperature | #6 |
| tear meniscus patients | #6 |
| chloride eye | #6 |
| bengal vital stainings | #6 |
| 4 muc | #6 |
| corneal fibroblasts pathogenesis | #6 |
| obstructive mgd patients | #6 |
| tacrolimus chronic | #6 |
| defect ped | #6 |
| itching conjunctival | #6 |
| levocabastine effective | #6 |
| severe vernal | #6 |
| coated elf | #6 |
| conjunctival diseases | #6 |
| oxidation hel | #6 |
| sac vkc | #6 |
| defect penetrating | #6 |
| rose bengal dyes | #6 |
| dust asian | #6 |
| remodeling vkc | #6 |
| findings dry eye | #6 |
| rate tbut | #6 |
| cyclosporine 01 | #6 |
| severe stevens | #6 |
| challenge cac | #6 |
| levels air pollutants | #6 |
| examinations tear | #6 |
| edema severity | #6 |
| hyperemia swelling | #6 |
| eyes atopic | #6 |
| conjunctival brush cytology | #6 |
| twicedaily instillation | #6 |
| july correlation | #6 |
| eosinophil recruiting chemokines | #6 |
| tear ecp | #6 |
| ecp markers | #6 |
| dressings female | #6 |
| symptoms vkc | #6 |
| betamethasone oral | #6 |
| controlling eyelid | #6 |
| instability conjunctival | #6 |
| antiallergic eye | #6 |
| elasticity cutometer | #6 |
| ointment blood | #6 |
| severe vkc | #6 |
| ocular fatigue | #6 |
| ocular surface findings | #6 |
| conjunctival confocal | #6 |
| tear stability values | #6 |
| hyperemia imidazoles | #6 |
| noninvasive suction device | #6 |
| severe ocular inflammation | #6 |
| eye evaluated | #6 |
| il4 il2r | #6 |
| induced tear | #6 |
| differences tear | #6 |
| fibroblasts conjunctival | #6 |
| pge2 cox2 levels | #7 |
| conclusion mmc | #7 |
| administration fluorescein | #7 |
| mmc 005 | #7 |
| alpha tears | #7 |
| nerves tear | #7 |
| rose bengal fluorescein | #7 |
| ulceration healthy | #7 |
| tmh measurements | #7 |
| crth2 normal | #7 |
| 10 clinical signs | #7 |
| nonparametric tears | #7 |
| cases preventing | #7 |
| gpc vkc | #7 |
| steroidal benzophenones | #7 |
| chemotaxis eosinophils | #7 |
| normal blinking | #7 |
| tear supply | #7 |
| ocular inflammatory disorder | #7 |
| conjunctival complications | #7 |
| concentrations conjunctival | #7 |
| age 325 years | #7 |
| western blotting nfκb | #7 |
| hyperemia adverse | #7 |
| conjunctiva brush | #7 |
| examination tear | #7 |
| vkc gpc | #7 |
| conjunctivitis dry | #7 |
| ulcer corneal | #7 |
| eczema frequently | #7 |
| eyelid surface | #7 |
| collected brush | #7 |
| procedures radioimmunoassay | #7 |
| allergic dna | #7 |
| status atopic | #7 |
| papillae formation | #7 |
| tacrolimus topical steroids | #7 |
| suspension 01 | #7 |
| sensation symptom | #7 |
| meniscometry testing | #7 |
| allergic eyelid | #7 |
| ulcers revealed | #7 |
| conjunctival inflammatory | #7 |
| adult blepharitis | #7 |
| 4 tear | #7 |
| surgery cooling | #7 |
| tears alpha | #7 |
| pgd2 dependent | #7 |
| development allergic conjunctivitis | #7 |
| necrotizing anterior | #7 |
| patients comfort level | #7 |
| tears th2 | #7 |
| sources chemokines | #7 |
| pathogenesis subsequent | #7 |
| incidence meibomian | #7 |
| mucins tears | #7 |
| improvements symptom scores | #7 |
| prostaglandin atopic | #7 |
| cytology differ | #7 |
| inhibitor ono2235 | #7 |
| revealed eosinophils | #7 |
| conjunctivitis risk | #7 |
| eyes ophthalmologists | #7 |
| conjunctival brush | #7 |
| mucins periodic | #7 |
| key prostaglandin | #7 |
| mmc observed | #7 |
| increases proliferative | #7 |
| superiority placebo | #7 |
| silicone plugs | #7 |
| solution bf | #7 |
| injection oedema | #7 |
| sensitization asian | #7 |
| severe persistent cases | #7 |
| neutrophils corneal | #7 |
| 0001 impression | #7 |
| accommodating intraocular lens | #7 |
| thought pathogenesis | #7 |
| evaluation eyelid | #7 |
| amniotic membrane patching | #7 |
| corneal lesion | #7 |
| tacrolimustreated eyes | #7 |
| attendance allergic | #7 |
| hrtii rcm | #7 |
| underwent tear | #8 |
| patients vkc | #8 |
| teros values | #8 |
| 4 chemokines | #8 |
| akc patients controls | #8 |
| patients corneal | #8 |
| graticule scale | #8 |
| conjunctival findings | #8 |
| ulcers detected | #8 |
| betamethasone calcineurin | #8 |
| values slit | #8 |
| transient burning sensation | #8 |
| hoc analysis study | #8 |
| itching hyperemia | #8 |
| blink patients | #8 |
| corneal ulcer | #8 |
| controls brush | #8 |
| classified allergic | #8 |
| limbalbased conjunctival flap | #8 |
| alterations allergic | #8 |
| infrared radiation thermometry | #8 |
| tnfalpha eosinophils | #8 |
| il4 enzyme | #8 |
| keratocytes cytokines | #8 |
| superficial cells groups | #8 |
| meniscometry scores | #8 |
| akc subjects | #8 |
| correlation vital | #8 |
| brush cytology | #8 |
| noninfectious corneal | #8 |
| pathogenesis test | #8 |
| flare counts | #8 |
| par2 mast cells | #8 |
| expressions thought | #8 |
| pollen odds | #8 |
| corneal fibroblasts tnfalpha | #8 |
| definite dry eye | #8 |
| occlusion lacrimal | #8 |
| eye redness | #8 |
| induced intraocular | #8 |
| asia cats | #8 |
| microscopy conjunctival | #8 |
| mitomycin post | #8 |
| meniscometry tear | #8 |
| corneal scores | #8 |
| blinking desiccation | #8 |
| ihc hel | #8 |
| conjunctivitis eyes | #8 |
| age 170 ± | #8 |
| blinking body | #8 |
| alterations cornea | #8 |
| ccl5 conjunctiva | #8 |
| trabeculectomy amniotic | #8 |
| radiation thermography | #8 |
| rollable intraocular | #8 |
| controls seldi | #8 |
| stainings schirmer | #8 |
| staining hel | #8 |
| techniques keratoconjunctivitis | #8 |
| fva measurements | #8 |
| oedema scores | #8 |
| fluorescein rose bengal | #8 |
| corneal epithelial lesions | #8 |
| teros | #8 |
| scores teros | #8 |
| surface teros | #8 |
| 006 degree | #8 |
| conjunctival sensation | #8 |
| diameter acinar | #8 |
| palpebral bulbar | #8 |
| stained hel | #8 |
| sac akc | #8 |
| allergic dibenzazepines | #8 |
| chemotaxis pgd2 | #8 |
| concentration tears | #9 |
| genes cxc | #9 |
| diseases conjunctivitis | #9 |
| hyperemia iop | #9 |
| sensitivity conjunctival | #9 |
| tnfalpha fibroblasts | #9 |
| sio2 pbs | #9 |
| wash solution | #9 |
| sensitivity confocal | #9 |
| cobblestone papillae | #9 |
| hel 4 | #9 |
| vital staining scores | #9 |
| tears thermography | #9 |
| 0001 schirmer | #9 |
| tear level | #9 |
| acid goblet | #9 |
| shield ulcers | #9 |
| cys eye | #9 |
| elisa tears | #9 |
| diagnosis conjunctivitis | #9 |
| injection edema | #9 |
| prevalence vkc | #9 |
| fluorescein rose | #9 |
| supply superior | #9 |
| pretreatment docosahexaenoic | #9 |
| level pollutants | #9 |
| glaucoma younger age | #9 |
| conjunctivitis cases | #9 |
| stress staining | #9 |
| sufficient examination | #9 |
| blood level tacrolimus | #9 |
| design eyelid | #9 |
| foreign body sensation | #9 |
| operatedon eye | #9 |
| clinical ocular findings | #9 |
| reductase cataract | #9 |
| fatigue dry | #9 |
| prospective study tacrolimus | #9 |
| prevalence weather | #9 |
| excision intraoperative | #9 |
| histocytological study | #9 |
| cases conjunctivitis | #9 |
| superior limbic | #9 |
| pathogen allergic | #9 |
| eye normal subjects | #9 |
| measurements vital | #9 |
| smart eye | #9 |
| observed obstructive | #9 |
| subjective ocular | #9 |
| tacrolimus 95 | #9 |
| crth2 expression eosinophils | #9 |
| specular microscopic evaluation | #9 |
| implantation 1cu | #9 |
| patients tacrolimus treatment | #9 |
| eye grade | #9 |
| symptoms allergic conjunctivitis | #9 |
| pilocarpine tablets | #9 |
| conjunctival fibroblast | #9 |
| pollution conjunctivitis | #9 |
| vital stainings | #9 |
| differ allergic | #9 |
| tacrolimus treating | #9 |
| received preserved | #9 |
| mmc recurrence | #9 |
| severity corneal | #9 |
| untreated asian | #9 |
| inflammation steroidal | #9 |
| ono2235 | #9 |
| muc16 muc5ac | #10 |
| bengal stainings | #10 |
| conjunctivitis histamine | #10 |
| incubated il4 | #10 |
| scale tear | #10 |
| iop hyperemia | #10 |
| icam1 tnfalpha | #10 |
| central graft | #10 |
| allergic ocular | #10 |
| functions dry | #10 |
| staining brush | #10 |
| drugs conjunctival | #10 |
| proliferation conjunctival | #10 |
| vmr values | #10 |
| evaluation atopic | #10 |
| sensation ocular | #10 |
| par2 mast | #10 |
| assessed conjunctival | #10 |
| tear cytology | #10 |
| levels tears | #10 |
| tears 10 | #10 |
| nonallergic conjunctivitis | #10 |
| conjunctivitis japan | #10 |
| staining oral | #10 |
| ophthalmic adolescent | #10 |
| aged conjunctivitis | #10 |
| eye clinically | #10 |
| eye surface | #10 |
| punctal occlusion | #10 |
| conjunctivitis atopic | #10 |
| status conjunctival | #10 |
| lacrimal puncta | #10 |
| underwent slit | #10 |
| leupeptin benzamidine | #10 |
| chemokines cxc chemokines | #10 |
| cornea eosinophils | #10 |
| topical cyclosporine patients | #10 |
| resection regrowth | #10 |
| allergic bronchitis | #10 |
| cytometry il4 | #10 |
| laminin actins | #10 |
| treatment vkc | #10 |
| muc5ac muc16 | #10 |
| humans mucin | #10 |
| total tear ige | #10 |
| crth2 chemotaxis | #10 |
| improvement tear | #10 |
| produced conjunctival | #10 |
| substance tears | #10 |
| layer alterations | #10 |
| conjunctival edema | #10 |
| visante optical | #10 |
| measuring tear | #10 |
| lower tmh | #10 |
| humans conjunctival | #10 |
| allergic conjunctivitis spring | #10 |
| conjunctivitis spring | #10 |
| insufficient local | #10 |
| compared eyes | #10 |
| measurement strip | #10 |
| patients ulcers | #10 |
| diagnosis dry eye | #10 |
| complain | #10 |
| subbasal stromal | #10 |
| shield ulcer | #10 |
| meibomian gland obstruction | #10 |
| eye infrared | #10 |
| 1 month reduction | #11 |
| vkc | #11 |
| coherence dry | #11 |
| function ocular | #11 |
| diagnosis allergic | #11 |
| elisa il4 | #11 |
| preserved artificial | #11 |
| smart eye camera | #11 |
| initiation tacrolimus | #11 |
| hel hne | #11 |
| purpose metaplasia | #11 |
| prevalence dry eye | #11 |
| matched dry | #11 |
| keratitis observed | #11 |
| patient atopic | #11 |
| vkc normal | #11 |
| disease edition | #11 |
| weeks papillary | #11 |
| ophthalmic solution | #11 |
| fibroblasts pathogenesis | #11 |
| tears conjunctival | #11 |
| association outpatient | #11 |
| vkc adolescent | #11 |
| therapy conjunctivitis | #11 |
| interleukin4 male | #11 |
| antivcaigg | #11 |
| surgery 13 eyes | #11 |
| anesthesia strabismus | #11 |
| elicited statistically | #11 |
| eosinophils prostaglandin | #11 |
| sensation tear | #11 |
| vmr fva | #11 |
| higher muc1 | #11 |
| cooling operation | #11 |
| schirmer1 test | #11 |
| lamp microscope | #11 |
| landolt visual | #11 |
| vernal | #11 |
| amniotic membrane patch | #11 |
| test tear | #11 |
| sensation staining | #11 |
| methods conjunctival | #11 |
| palpebral bulbar conjunctiva | #11 |
| count conjunctivitis | #11 |
| vcam1 tnfalpha | #11 |
| genes corneal | #11 |
| levocabastine hydrochloride | #11 |
| drop artificial | #11 |
| common conjunctival | #11 |
| elasticity treatment | #11 |
| cytometry oligonucleotide | #11 |
| radiography tears | #12 |
| leupeptins mast | #12 |
| conventional slit | #12 |
| severe binocular | #12 |
| 1821 subjects | #12 |
| corneal aesthesiometry | #12 |
| eye diagnosed | #12 |
| expression 8 genes | #12 |
| extracts pollens | #12 |
| drugs pge2 | #12 |
| density muc5ac | #12 |
| 1cu iol | #12 |
| supratarsal injection | #12 |
| findings conjunctival | #12 |
| controls antibody titers | #12 |
| acids chemokine | #12 |
| surface diabetic | #12 |
| coated lactoferrin | #12 |
| levocabastine patients | #12 |
| density acinar | #12 |
| keratoconjunctivitis patients | #12 |
| biomarker allergic | #12 |
| immunologic rejection | #12 |
| fva visual | #12 |
| mmhg elevation | #12 |
| fva vmr | #12 |
| lacrimal punctal | #12 |
| selected severity | #12 |
| appearance atopic | #12 |
| 001 specimens | #12 |
| projects tears | #12 |
| ccl11 conjunctiva | #12 |
| conjunctival injection | #12 |
| cornea density | #12 |
| highspeed highresolution | #12 |
| receptor crth2 | #12 |
| corneal shield | #12 |
| dermatitis tacrolimus | #12 |
| patients sac | #12 |
| ulcers squamous | #12 |
| damage height | #12 |
| 002 ophthalmic | #12 |
| pemirolast potassium | #12 |
| mgd controls | #12 |
| tears conjunctivitis | #12 |
| iop younger | #12 |
| microscopy efficient | #12 |
| iop glucocorticoids humans | #12 |
| specimens eyes | #12 |
| keratoplasty glaucoma | #12 |
| 1cu accommodating | #12 |
| fluorescein scores | #12 |
| sd105 | #13 |
| glaucoma keratoplasty | #13 |
| compared postsurgical | #13 |
| improvement vital | #13 |
| time fluorescein | #13 |
| syndrome reactivation | #13 |
| thirty eyes | #13 |
| keratocytes incubated | #13 |
| tear functions | #13 |
| coherence viscosupplements | #13 |
| symptoms conjunctival | #13 |
| temperature cataract | #13 |
| topical cyclosporine treatment | #13 |
| conclusions ocular | #13 |
| schirmers test values | #13 |
| months healed | #13 |
| 5ac ophthalmic | #13 |
| upper tarsal | #13 |
| ulcers corneal | #13 |
| scraped samples | #13 |
| applied operation | #13 |
| bengal fluorescein | #13 |
| tear hel | #13 |
| fluorometholone fml | #13 |
| remodeling relevant | #13 |
| chemokines stimulation | #13 |
| inflammation tear | #13 |
| interferometry tear | #13 |
| dry eye examination | #13 |
| glaucoma younger | #13 |
| week corneal | #13 |
| japan keratoconjunctivitis | #13 |
| specimens levels | #13 |
| epithelial disease | #13 |
| protein conjunctival | #13 |
| conjunctival oedema | #13 |
| papillary samples | #13 |
| stability vital | #13 |
| vmr measurements | #13 |
| suspensions tacrolimus | #13 |
| anterior segment photography | #13 |
| outcomes 01 | #13 |
| aged disposable | #13 |
| blood levels tacrolimus | #13 |
| called giant | #13 |
| cell flare | #13 |
| corneal complications | #13 |
| objective signs | #13 |
| treatment allergic conjunctivitis | #13 |
| mcfg treatment | #14 |
| epithelial muc5ac | #14 |
| schirmer1 | #14 |
| functions corneal | #14 |
| conjunctivitis vernal | #14 |
| conjunctival muc5ac | #14 |
| dry eye controls | #14 |
| factors conjunctivitis | #14 |
| test rose | #14 |
| pilocarpine effective | #14 |
| blinking patients | #14 |
| cornea endophthalmitis | #14 |
| benzamidines blotting | #14 |
| eyes 002 | #14 |
| radioimmunoassay tears | #14 |
| conjunctivitis background | #14 |
| fungi adolescent | #14 |
| clinically allergic | #14 |
| fibroblast damage | #14 |
| occlusion dry | #14 |
| solutions retrospective | #14 |
| 14 flare | #14 |
| fluorometholone humans | #14 |
| secrete mediators | #14 |
| visits allergic | #14 |
| flare count | #14 |
| higher allergic | #14 |
| proliferative lesion | #14 |
| conjunctival allergen challenge | #14 |
| vehicle eye | #14 |
| bf 01 | #14 |
| conjunctival impression | #14 |
| clinical corneal | #14 |
| density tear | #14 |
| eye drop treatment | #15 |
| damaged fibroblasts | #15 |
| steroidal cornea | #15 |
| adherence fibroblasts | #15 |
| tmh values | #15 |
| examined existence | #15 |
| patients vernal | #15 |
| receptor pgd2 | #15 |
| evaluation conjunctival | #15 |
| superior conjunctiva | #15 |
| improvement subjective symptoms | #15 |
| improvement corneal | #15 |
| firstline drug | #15 |
| rtpcr cytometry | #15 |
| bilateral conjunctivitis | #15 |
| ocular surface mucins | #15 |
| diseases 2020 | #15 |
| giant papillary | #15 |
| correlation tear | #15 |
| blepharitis conjunctivitis | #15 |
| ocular itching | #15 |
| occlusion rose | #15 |
| mmc female follow | #15 |
| surface vital | #15 |
| effects benzalkonium | #15 |
| ige ecp | #15 |
| irritation scores | #15 |
| day bf | #15 |
| agents blepharitis | #15 |
| topical 01 | #15 |
| expression realtime pcr | #15 |
| vkc methods | #15 |
| basal tear secretion | #15 |
| olopatadine 01 | #15 |
| corneal recurrence | #15 |
| tranilast anti | #15 |
| cytology brush | #15 |
| ophthalmology tokyo | #15 |
| ocular acrylic | #15 |
| bromobenzenes child | #15 |
| ulcer echinocandins | #15 |
| monitoring tear | #15 |
| analysis par2 | #15 |
| occlusion oct | #15 |
| complications mmc | #15 |
| investigated corneal | #15 |
| mucous discharge | #15 |
| complications height | #15 |
| measurements tear | #16 |
| assessment conjunctival | #16 |
| eosinophils receptor | #16 |
| objective ocular | #16 |
| ari administration | #16 |
| ige correlation | #16 |
| segment photography | #16 |
| hours visit | #16 |
| 2 conjunctival | #16 |
| lacrimation | #16 |
| total clinical scores | #16 |
| odds ratio remission | #16 |
| patients vernal keratoconjunctivitis | #16 |
| reduction goblet | #16 |
| ulcers positive | #16 |
| safety 01 | #16 |
| alpha ortho | #16 |
| controls papillary | #16 |
| fungi odds | #16 |
| female goblet | #16 |
| dust allergic | #16 |
| temperature conjunctiva | #16 |
| treatment eyelid | #16 |
| expression eotaxin1 | #17 |
| age dry | #17 |
| agents cedrus | #17 |
| ocular allergic inflammation | #17 |
| signs ded | #17 |
| clearance corneal | #17 |
| corneal sensation | #17 |
| conjunctival samples | #17 |
| warmer treatment | #17 |
| drops eyes | #17 |
| staining muc1 | #17 |
| evaluation inflammatory | #17 |
| 13 females age | #17 |
| fibroblasts mcp1 | #17 |
| strip meniscometry | #17 |
| betamethasone induced | #17 |
| 20 normal patients | #17 |
| eyes schirmer | #17 |
| fibroblasts damaged | #17 |
| analyzed 005 | #17 |
| increased goblet cells | #17 |
| ceramide gel | #17 |
| sclera trabeculectomy | #17 |
| inhibitor ari | #17 |
| muc16 mrna | #17 |
| inflammation blotting | #17 |
| wear soft | #17 |
| initiation objective | #17 |
| meniscometry | #17 |
| fibroblasts giant | #18 |
| technique glaucoma | #18 |
| tear function | #18 |
| cytology decrease | #18 |
| tnfα inflammatory response | #18 |
| bengal sjogren | #18 |
| lower eyes | #18 |
| ulcers compared | #18 |
| conclusion ocular | #18 |
| intraoperative 002 | #18 |
| differentiation inflammatory cells | #18 |
| inflammation lenses | #18 |
| types dry eye | #18 |
| rantes response | #18 |
| ocular surface status | #18 |
| associations level | #18 |
| higher tears | #18 |
| noncl wearers | #18 |
| male ophthalmic solutions | #18 |
| obstructive dysfunction | #18 |
| 30 ige | #18 |
| pollen fungi | #18 |
| test tears | #18 |
| correlation clinical signs | #18 |
| complete staining | #18 |
| groups spt | #18 |
| trabeculectomy glaucoma | #18 |
| induce corneal | #18 |
| concentrations corneal | #18 |
| studies rose | #18 |
| ulceration subjects | #18 |
| cd45 inflammatory | #18 |
| decrease ocular | #18 |
| dibenzazepines dibenzoxepins | #18 |
| tear evaporation rate | #18 |
| cytology corneal | #18 |
| evaluation tear | #18 |
| sodium 01 | #19 |
| staining scores | #19 |
| limbal allograft | #19 |
| eosinophils adhered | #19 |
| early efficacy | #19 |
| aged ophthalmic | #19 |
| aged cautery | #19 |
| steroid female | #19 |
| 1151 years | #19 |
| seldi proteinchip | #19 |
| mitomycin ophthalmologic | #19 |
| microscopy scans | #19 |
| periostin biomarker | #19 |
| dha pretreatment | #19 |
| prospective study eyes | #19 |
| conjunctivitis topical | #19 |
| evaluated infrared | #19 |
| inflammatory cells patients | #19 |
| total signs | #19 |
| subjects underwent | #19 |
| temperature artificial | #19 |
| operation applied | #19 |
| beta1 il1beta | #19 |
| ige tear | #19 |
| outpatient attendance | #19 |
| 3 severe | #19 |
| effective tacrolimus | #19 |
| vernal keratoconjunctivitis | #19 |
| seldi analysis | #19 |
| sma performed | #19 |
| measurements visante | #19 |
| human conjunctival | #19 |
| proteins tears | #20 |
| treated 01 | #20 |
| symptoms allergic | #20 |
| explain pathogenesis | #20 |
| persistent epithelial defect | #20 |
| allergic female humans | #20 |
| plaques graded | #20 |
| lower dry | #20 |
| decreased conjunctival | #20 |
| corneal impression | #20 |
| common ocular disorders | #20 |
| evaluate noninferiority | #20 |
| tears corneal | #20 |
| ulcers cell | #20 |
| xerophthalmia adolescent | #20 |
| summarized based | #20 |
| vernal keratoconjunctivitis vkc | #20 |
| conjunctivitis primary | #20 |
| patients strip | #20 |
| conjunctivitis caused | #20 |
| improvements ocular | #20 |
| cytology upper | #20 |
| bilateral agerelated cataract | #20 |
| surface findings | #20 |
| pollen association | #20 |
| echinocandins eye | #20 |
| mucin alterations | #20 |
| 022 pg | #20 |
| height tmh | #20 |
| conclusion tacrolimus | #20 |
| levels hel | #21 |
| preventing corneal | #21 |
| cornea clinical | #21 |
| tears blood | #21 |
| keratoconjunctivitis atopic | #21 |
| methane nonmethane hydrocarbons | #21 |
| induced topical | #21 |
| eosinophils flow cytometry | #21 |
| ocular symptoms signs | #21 |
| conclusions topical | #21 |
| symptoms include | #21 |
| fluorescence postoperative | #21 |
| microscopy patients | #21 |
| patients concomitant treatment | #21 |
| lipid oxidative | #21 |
| radiation thermometer | #21 |
| peripheral blood eosinophils | #21 |
| film lipid | #21 |
| eye smaller | #21 |
| reduction topical | #21 |
| eye control | #21 |
| acuity assessment | #21 |
| ige groups | #21 |
| cultured conjunctiva | #21 |
| surface mucin | #21 |
| crth2 expressed | #21 |
| patients cedar | #21 |
| adhesion fibroblast | #21 |
| conjunctiva role | #21 |
| reaction tears | #21 |
| mgd adult | #22 |
| serum periostin patients | #22 |
| negative lower | #22 |
| accommodation amplitude | #22 |
| fluorescein staining | #22 |
| haze photorefractive | #22 |
| correlation humidity | #22 |
| eyes nerve | #22 |
| types ocular | #22 |
| 01 tacrolimus | #22 |
| 005 topical | #22 |
| muc5ac patients | #22 |
| fibroblasts anti | #22 |
| therapies allergic | #22 |
| epithelial lipid | #22 |
| flare anterior | #22 |
| preschool conjunctivitis | #23 |
| solution corneal | #23 |
| prospectively surgery | #23 |
| 5 females | #23 |
| tear dynamics | #23 |
| labeling tears | #23 |
| lamp examinations | #23 |
| 215 ± | #23 |
| hrt confocal | #23 |
| tests adenovirus | #23 |
| disease atopic | #23 |
| function mucin | #23 |
| il4 tnf | #23 |
| layer interferometry | #23 |
| patients topical steroids | #23 |
| score deqs | #23 |
| subjects squamous | #23 |
| palpebral conjunctiva | #23 |
| 01 severe | #23 |
| cooling applied | #23 |
| corneal fluorescein | #23 |
| pge2 supernatants | #23 |
| diseases diclofenac | #23 |
| blood concentration tacrolimus | #23 |
| solution compared | #23 |
| interleukin4 oligonucleotide | #24 |
| tokyo dental | #24 |
| cell meter | #24 |
| layer tear | #24 |
| fungal corneal | #24 |
| signs serum | #24 |
| diseases web | #24 |
| patients tacrolimus ointment | #24 |
| 27yearold male patient | #24 |
| histamine development | #24 |
| ocular allergies | #24 |
| local allergic reaction | #24 |
| edema drug | #24 |
| formation allergic | #24 |
| warming device | #24 |
| vital staining | #24 |
| samples conjunctival | #24 |
| vkc patients | #24 |
| tarsal conjunctiva | #24 |
| surface tear | #24 |
| dermatitis improved | #24 |
| conjunctiva diabetes | #24 |
| control tear | #24 |
| bengal tears | #24 |
| corneal plaques | #25 |
| slitlamp examinations | #25 |
| steroid eye | #25 |
| level tears | #25 |
| antigen conjunctiva | #25 |
| atopic eosinophils humans | #25 |
| protein rtpcr | #25 |
| schedule eosinophil | #25 |
| density squamous | #25 |
| eyes epithelial | #25 |
| 0001 dry | #25 |
| confocal prospective | #25 |
| patients atopic diseases | #25 |
| bengal scores | #25 |
| superficial cells | #25 |
| rsv rtpcr | #25 |
| dynamics tear | #25 |
| vkc compared | #25 |
| staining goblet | #25 |
| vcam1 activated | #25 |
| rtpcr rsv | #25 |
| singletreatment groups | #26 |
| symptoms itching | #26 |
| human α defensin | #26 |
| 100 nylon | #26 |
| 005 immunoreactive | #26 |
| conjunctivitis | #26 |
| statistical decrease | #26 |
| diseases ambient | #26 |
| acinar unit | #26 |
| postkeratoplasty glaucoma | #26 |
| corneal ulcers | #26 |
| level il4 | #26 |
| smallincision cataract surgery | #26 |
| conjunctival inflammation | #26 |
| specific ige positivity | #26 |
| subjects measuring | #26 |
| keratoconjunctivitis caused | #26 |
| lnfs | #26 |
| slit lamp examinations | #26 |
| solutions corneal | #26 |
| conclusions improvement | #26 |
| eyes topical | #26 |
| actins collagen | #26 |
| dmem f12 medium | #26 |
| tbut tear | #26 |
| aureus detected | #26 |
| correlated corneal | #26 |
| rapid epithelialization | #26 |
| 01 topical | #26 |
| damage adhesion | #26 |
| adhered fibroblasts | #26 |
| treatment meibomian | #26 |
| wheal diameter | #26 |
| alpha eosinophils | #27 |
| reaction sensation | #27 |
| oct prospective | #27 |
| 005 symptoms | #27 |
| epinastine | #27 |
| interleukin4 polymerase | #27 |
| conjunctival epithelial | #27 |
| tear ocular | #27 |
| factor exacerbation | #27 |
| therapy conjunctiva | #27 |
| child cytological | #27 |
| antibodies brush | #27 |
| associations prevalence | #27 |
| 01 cyclosporine | #27 |
| cytometry chemotaxis | #27 |
| lymphocytes specimens | #27 |
| prescribed topical | #27 |
| density subbasal | #27 |
| eosinophils fibroblasts | #27 |
| eosinophil adherence | #28 |
| assessment tear | #28 |
| assay eosinophils | #28 |
| underwent immunohistochemical | #28 |
| objective scores | #28 |
| ophthalmic | #28 |
| stress atopic | #28 |
| chemotactic activity eosinophils | #28 |
| provide relief | #28 |
| conjunctiva dexamethasone | #28 |
| 2 iol | #28 |
| prevalence allergic diseases | #28 |
| 4 5ac | #28 |
| solutions ophthalmologic | #28 |
| diseases proliferative | #28 |
| corneal ulceration | #28 |
| corneal vivo | #28 |
| severe ocular | #28 |
| papillae patients | #28 |
| conjunctival epithelial cells | #28 |
| il13 il1beta | #28 |
| giant papillae | #28 |
| flare cell | #29 |
| rosebengal | #29 |
| corneal conjunctival | #29 |
| aged thermography | #29 |
| cys treatment | #29 |
| eye mask | #29 |
| conjunctiva dose | #29 |
| numbers inflammatory | #29 |
| ketotifen fumarate | #29 |
| performed morphometric | #29 |
| thermography adolescent | #29 |
| scores schirmer | #29 |
| disease periostin | #29 |
| studies conjunctivitis | #29 |
| inhibited tranilast | #29 |
| 5ac mucins | #29 |
| sac compared | #29 |
| allergic regulation | #29 |
| redness eye | #30 |
| expressed crth2 | #30 |
| conjunctivitis humans | #30 |
| minutes visit | #30 |
| inhibitors pollen | #30 |
| il2r serum | #30 |
| tear serum | #30 |
| eye common | #30 |
| conjunctiva cells | #30 |
| effective artificial | #30 |
| atopic diagnostic | #30 |
| ocular surface alterations | #30 |
| symptoms accompanying | #30 |
| infection conjunctival | #30 |
| syndromes equipment | #30 |
| regrowth observed | #30 |
| conjunctivitis patients | #30 |
| recruitment day | #30 |
| palpebral | #30 |
| fibroblasts protease | #30 |
| common adverse reaction | #30 |
| dermatitis efficacy | #30 |
| tear ige | #30 |
| specificity tears | #30 |
| mucins ophthalmic | #30 |
| levels july | #31 |
| neutrophils severity | #31 |
| atopic 10 | #31 |
| disease summarized | #31 |
| combinations eosinophils | #31 |
| hel levels | #31 |
| vegf cultured | #31 |
| scores corneal | #31 |
| schirmer scores | #31 |
| acuity fva | #31 |
| fibroblasts pcr | #31 |
| properties tears | #31 |
| pathogenesis corneal | #31 |
| inflammation atopic | #31 |
| dermatitis purpose | #31 |
| ige negative | #31 |
| meibomian gland secretion | #31 |
| expressed eosinophils | #31 |
| worse observed | #31 |
| epithelial mucins | #31 |
| analysis tears | #32 |
| substantial interrater agreement | #32 |
| western blotting effects | #32 |
| eye sjögren | #32 |
| prostaglandin cell | #32 |
| sign scores | #32 |
| diagnosed dry | #32 |
| signs improved | #32 |
| deqs | #32 |
| keratoconjunctivitis | #32 |
| conjunctival cells | #32 |
| tgfbeta1 il1beta | #32 |
| tear meniscus height | #32 |
| reduced steroid | #32 |
| expressibility | #32 |
| limbus cornea | #32 |
| schirmer test values | #32 |
| ige histamine | #33 |
| atopic skin disease | #33 |
| allergic double | #33 |
| iop induced | #33 |
| muc 1 | #33 |
| levocabastine | #33 |
| signs evaluated | #33 |
| edema correlated | #33 |
| film break | #33 |
| count prostaglandin | #33 |
| 4 grades | #33 |
| visante | #33 |
| conclusions confocal | #33 |
| immunoglobulin interferometry | #33 |
| numbers quantitative | #33 |
| seasonal young | #33 |
| haze score | #33 |
| 10 objective | #34 |
| bengal staining | #34 |
| fluorometholone glucocorticoids | #34 |
| il1beta tgfbeta1 | #34 |
| eye 10 | #34 |
| proteinchip array | #34 |
| clinical signs patients | #34 |
| alpha fibroblasts | #34 |
| treatment mgd | #34 |
| eyes corneal | #34 |
| therapy histamine | #34 |
| intraocular pressure surgery | #34 |
| conjunctiva cytokines | #34 |
| 01 effective | #34 |
| fibroblasts purpose | #34 |
| interrater reproducibility | #35 |
| hypertension tacrolimus | #35 |
| mucins prospective | #35 |
| cyclosporine cys | #35 |
| objective symptoms | #35 |
| tear stability | #35 |
| 6 months conclusion | #35 |
| virus capsid antigen | #35 |
| eye 20 | #35 |
| adult asthenopia | #35 |
| eyes acrysof | #36 |
| schirmer 1 | #36 |
| functional visual acuity | #36 |
| tear samples | #36 |
| severe allergic | #36 |
| anterior scleritis | #36 |
| tear clearance | #36 |
| ocular surface inflammation | #36 |
| measured tear | #36 |
| differential dry | #36 |
| efficacy groups | #36 |
| humans keratoconjunctivitis | #36 |
| diseases eosinophil | #36 |
| vdt users | #36 |
| resection 005 | #36 |
| induced iop | #37 |
| conducted compliance | #37 |
| wellrecognized risk | #37 |
| laser flarecell meter | #37 |
| recurrence corneal | #37 |
| tacrolimus 12 | #37 |
| oct effective | #37 |
| contact lens surface | #37 |
| tears tumor | #37 |
| 002 mmc | #37 |
| delefilcon | #37 |
| scleritis episcleritis | #37 |
| schirmer 1 test | #37 |
| tenon anesthesia | #37 |
| eyelid skin | #37 |
| post cataract | #38 |
| aged olopatadine | #38 |
| gland lipid | #38 |
| phacoemulsification implantation | #38 |
| device eye | #38 |
| 002 mitomycin | #38 |
| allergic cromolyn | #38 |
| exhibited correlation | #38 |
| pemirolast | #38 |
| cac japanese | #38 |
| response pretreatment | #39 |
| cells conjunctiva | #39 |
| 0001 specimens | #39 |
| degree 20 | #39 |
| conjunctiva limbus | #39 |
| cyclosporine dry | #39 |
| infiltration corneal | #39 |
| patients dry eye | #39 |
| tests diagnostic accuracy | #39 |
| accommodating intraocular | #39 |
| atopic dry | #39 |
| solutions patient | #39 |
| 005 oct | #39 |
| tears eye | #39 |
| tmh | #40 |
| acid chemokine | #40 |
| subjects specimens | #40 |
| ulcers control | #40 |
| decreased inflammation | #40 |
| endothelial rejection | #40 |
| samples eyes | #40 |
| drops corneal | #40 |
| eye patients | #40 |
| biomarkers conjunctiva | #40 |
| pharmacology clinical efficacy | #40 |
| ecp concentrations | #41 |
| conjunctivitis gpc | #41 |
| pollution severe | #41 |
| stimulate vascular | #41 |
| vegf il1beta | #41 |
| homologous visual | #41 |
| α pge2 | #41 |
| il1beta vegf | #41 |
| treated topical | #41 |
| treatment dry | #41 |
| eyes superior | #41 |
| epitheliopathy | #41 |
| efficient noninvasive | #42 |
| day eye | #42 |
| break time | #42 |
| allergens conjunctivitis | #42 |
| october july | #42 |
| corneal epithelia | #42 |
| scans underwent | #42 |
| rollable | #43 |
| eyelid edema | #43 |
| hydrocarbons data | #43 |
| instability decreased | #43 |
| keratolimbal | #43 |
| limbus corneal | #43 |
| conjunctival hyperemia | #43 |
| cytology revealed | #43 |
| meniscus treatment | #43 |
| revised 2010 | #43 |
| surface years | #43 |
| diseases 2017 | #43 |
| microscopy central | #43 |
| cautery female | #44 |
| activated il4 | #44 |
| eye 0001 | #44 |
| oct assessment | #44 |
| collagens fibronectin | #44 |
| tear meniscus | #44 |
| abovementioned drugs | #44 |
| il1beta il4 | #44 |
| tryptase par2 | #44 |
| elasticity patients | #44 |
| agents keratoconjunctivitis | #44 |
| tacrolimus treatment | #44 |
| epithelial defect | #44 |
| subjective symptom | #44 |
| patients rhinoconjunctivitis | #44 |
| 24 seconds | #45 |
| micafungin mcfg | #45 |
| users contact | #45 |
| case corneal | #45 |
| fourgrade scale | #45 |
| inflammation ocular surface | #45 |
| body sensation | #45 |
| elevation iop | #45 |
| superficial punctate keratitis | #45 |
| japan particulate | #45 |
| rose bengal staining | #45 |
| fibroblasts eosinophils | #45 |
| laser microscopy | #45 |
| signs score | #45 |
| fibroblasts expression | #45 |
| surface inflammation | #45 |
| metaplasia mucin | #45 |
| surgery uncorrected | #45 |
| correlation inflammation | #45 |
| bovine enteric | #45 |
| recruiting chemokines | #45 |
| adult chemotaxis | #45 |
| formation corneal | #45 |
| topical tacrolimus treatment | #45 |
| metaplasia grade | #45 |
| understanding ocular | #45 |
| graded 3 | #45 |
| status ocular | #46 |
| efficacy 01 | #46 |
| suspension effective | #46 |
| tryptases regulation | #46 |
| seconds controls | #46 |
| 17 japanese patients | #46 |
| conjunctival | #46 |
| il13 serum | #46 |
| efficacy combined therapy | #46 |
| posttreatment findings | #46 |
| corneal cells | #46 |
| graticule | #46 |
| staining conjunctival | #46 |
| surface disease | #46 |
| fluorometholone | #46 |
| staining inflammatory | #46 |
| positive muc5ac | #47 |
| rate ocular | #47 |
| allergic female histamine | #47 |
| patients 01 | #47 |
| suspension 4 | #47 |
| diameter plant | #47 |
| blood level | #47 |
| visante oct | #47 |
| purpose efficacy | #47 |
| ulcer score | #47 |
| complications corneal | #48 |
| sac patients | #48 |
| dexamethasone anti | #48 |
| enhanced benefits | #48 |
| cyclosporine ophthalmic | #48 |
| stromal nerve | #48 |
| eyes month | #48 |
| implantation acrysof | #48 |
| brush cytology specimens | #48 |
| muc5ac mrna | #48 |
| stimulation chemokine | #48 |
| eyelid warming | #48 |
| ocular signs | #49 |
| eosinophils epithelium | #49 |
| tacrolimus female | #49 |
| concentrations tears | #49 |
| fibroblasts incubated | #49 |
| adult ca125 | #49 |
| visits air | #49 |
| male tears | #49 |
| keratocytes fibroblasts | #49 |
| cxc chemokine genes | #49 |
| objective findings | #49 |
| 1cu | #49 |
| expression crth2 | #49 |
| trabeculectomy eyes | #49 |
| inflammation conjunctiva | #50 |
| aged blinking | #50 |
| test ocular | #50 |
| dyes fluorophotometry | #50 |
| trabeculectomy mitomycin | #50 |
| schirmers test | #50 |
| disposable soft | #50 |
| patient eyes | #50 |
| 4 normal controls | #50 |
| measuring corneal | #50 |
| total severity score | #50 |
| decreased tear | #50 |
| ulcers purpose | #50 |
| meniscus height | #50 |
| crth2 expression | #51 |
| periostin patients | #51 |
| effects docosahexaenoic acid | #51 |
| cells brush | #51 |
| members japan | #51 |
| diagnosis dry | #51 |
| lenses scls | #51 |
| ocular surface cells | #51 |
| reduction score | #51 |
| markers atopic | #51 |
| inflammation cataract | #51 |
| scls | #51 |
| tears tomography | #52 |
| reaction vehicle | #52 |
| atopic groups | #52 |
| month initiation | #52 |
| biomarker diseases | #52 |
| examination parameters | #52 |
| stability corneal | #52 |
| inflammation decline | #52 |
| severity objective | #52 |
| pcr tgf | #52 |
| eye normal | #52 |
| eyelid margins | #52 |
| bromfenac | #53 |
| differential eosinophil | #53 |
| acuity values | #53 |
| stromal nerves | #53 |
| scores tear | #54 |
| chloride bak | #54 |
| lacrimal glands | #54 |
| oxidation adolescent | #54 |
| obstructive mgd | #54 |
| 005 month | #54 |
| vegf protein secretion | #54 |
| presence rsv | #54 |
| limbic keratoconjunctivitis | #54 |
| suspension treatment | #54 |
| atopic enterotoxins | #55 |
| antagonists allergic | #55 |
| local cytokine production | #55 |
| epithelial cells expression | #55 |
| ocular signs symptoms | #55 |
| combinedtreatment | #55 |
| surface clinical | #55 |
| conjunctiva drug | #55 |
| adult conjunctivitis | #55 |
| aged pollen | #55 |
| solution placebo | #56 |
| dysfunction atopic | #56 |
| pain photophobia | #56 |
| allergies adolescent | #56 |
| ded adult | #56 |
| mucin layer | #56 |
| eosinophil cationic | #56 |
| atopic patients | #56 |
| 3 dry | #56 |
| specular microscopic | #56 |
| cornea cyclooxygenase | #56 |
| mucin2 mucin4 | #56 |
| plant pollens | #56 |
| mechanism giant | #56 |
| topical adolescent | #56 |
| film ocular | #56 |
| giant papillary conjunctivitis | #57 |
| insensible administration | #57 |
| inflammation pge2 | #57 |
| accommodating iol | #57 |
| chemotactic responses | #57 |
| penetrating limbus | #57 |
| humans interleukin4 | #57 |
| papilla formation | #58 |
| maximum blood concentration | #58 |
| schiff staining | #58 |
| drop treatment | #58 |
| staining tear | #58 |
| seventyeight eyes | #58 |
| alpha defensins | #58 |
| objective sign | #58 |
| type allergic | #59 |
| findings criteria | #59 |
| intraoperative mitomycin | #59 |
| disease eyes | #59 |
| pm25 prevalence | #59 |
| tear instability | #59 |
| signs severe | #60 |
| evaluation items | #60 |
| diabetic corneal | #60 |
| mmc 2 | #60 |
| syndromes female | #60 |
| daily disposable | #60 |
| pcr severe | #60 |
| compared 0001 | #60 |
| release inhibitor | #60 |
| tacrolimus ointment treatment | #60 |
| correlation patients | #61 |
| nonsteroidal blotting | #61 |
| thermography adult | #61 |
| punctal | #61 |
| specimens histopathologic | #62 |
| prostaglandin patients | #62 |
| allergen mediated | #62 |
| expression eyes | #62 |
| amplitude accommodation | #62 |
| total clinical | #62 |
| combination epithelium | #62 |
| values tended | #62 |
| eyes 16 | #62 |
| eotaxin1 expression | #62 |
| sac age | #63 |
| oral pilocarpine | #63 |
| chamber body | #63 |
| corneal stem | #63 |
| patient corneal | #63 |
| ulcer endophthalmitis | #63 |
| micafungin treatment | #63 |
| il4 role | #63 |
| corneal erosion | #63 |
| conjunctiva patients | #63 |
| hypersensitivity japan | #63 |
| cornea dry | #64 |
| radioimmunoassay respiratory | #64 |
| density inflammatory | #64 |
| factor allergic | #64 |
| eye adolescent | #64 |
| evaluation corneal | #64 |
| il4 culture | #64 |
| dexamethasone production | #64 |
| positive mucin | #64 |
| viral radioimmunoassay | #65 |
| conclusions corneal | #65 |
| microscope methods | #65 |
| live rsv | #65 |
| mucins rna | #65 |
| tears biomarkers | #65 |
| dust house | #65 |
| surface epithelial | #66 |
| layer speed | #66 |
| treatment immunosuppressive agents | #66 |
| diagnosis therapies | #66 |
| cases atopic | #66 |
| 003 treatment | #67 |
| agents keratoplasty | #67 |
| persistent epithelial | #67 |
| period oral | #67 |
| female fluorophotometry | #67 |
| effects 01 | #67 |
| cyclosporine eye | #67 |
| time vital | #68 |
| ointment treatment | #68 |
| housedust | #68 |
| eye dry | #68 |
| patients eosinophils | #69 |
| occlusion 005 | #69 |
| counter drugs | #69 |
| aged tears | #69 |
| fibroblasts examined | #69 |
| ophthalmic solutions | #69 |
| glaucoma graft | #69 |
| fibroblasts corneal | #69 |
| values rose | #70 |
| crth2 pgd2 | #70 |
| schirmer test | #70 |
| crth2 receptor | #70 |
| 22 eyes | #70 |
| rhinoconjunctivitis allergic | #70 |
| 1436 patients | #70 |
| visit 4 | #70 |
| dust 20 | #71 |
| drops treatment | #71 |
| allergic dermatitis | #71 |
| lenses dry | #71 |
| factors tears | #71 |
| tear production | #72 |
| bulbar conjunctiva | #72 |
| 16 eyes | #72 |
| ige eosinophil | #72 |
| glaucoma trabeculectomy | #72 |
| punctate keratopathy | #73 |
| immunosuppressive treatment patients | #73 |
| fluorophotometry humans | #73 |
| antiallergic agent | #73 |
| pyridines pyrimidinones | #73 |
| epithelial structure | #73 |
| pollution prevalence | #73 |
| liquid conjunctiva | #73 |
| fml | #73 |
| extraction conjunctiva | #73 |
| surface mucins | #73 |
| eosinophils expressed | #74 |
| evaluation dry | #74 |
| mcfg | #74 |
| tacrolimus patients | #74 |
| agents intraocular | #74 |
| inflammatory cell numbers | #74 |
| iol acrysof | #74 |
| laser flare | #75 |
| cedar pollen | #75 |
| dust epidemiologic | #75 |
| completely controlled | #75 |
| improved infrared | #75 |
| 1 month baseline | #75 |
| pilocarpine prospective | #75 |
| healthy individuals patients | #75 |
| agents interleukin4 | #76 |
| interleukin4 rna | #76 |
| guidelines allergic | #76 |
| ccchemokine | #76 |
| studies suspensions | #77 |
| vegf tgfbeta1 | #77 |
| ophthalmological elasticity | #77 |
| chemical mediator | #77 |
| slight elongation | #77 |
| signs treatment | #77 |
| cytokines stimulate | #77 |
| lower tear | #77 |
| excision recurrence | #77 |
| cytology samples | #77 |
| capilia | #77 |
| cornea module | #77 |
| surgery technique | #77 |
| signs observed | #78 |
| japanese guideline | #78 |
| concomitant tacrolimus | #78 |
| severity ocular | #78 |
| concentration il2 | #78 |
| drops 1 | #78 |
| pollen compared | #78 |
| extended wear | #79 |
| glaucoma penetrating | #79 |
| ocular pain | #79 |
| allergic environmental | #79 |
| effects corneal | #79 |
| permeability cornea | #79 |
| type allergy | #79 |
| dry eye | #79 |
| il4 ige | #79 |
| injection reduction | #79 |
| inhibitors leupeptin | #79 |
| mediated par2 | #80 |
| mgd patients | #80 |
| assay epithelial | #80 |
| questionnaires tears | #80 |
| medications required | #80 |
| decreased dry | #81 |
| vegf concentration | #81 |
| antigens histamine | #81 |
| caused insufficient | #82 |
| atopic dermatitis study | #82 |
| patients conjunctivitis | #82 |
| prostaglandin reverse | #82 |
| acrysof iol | #82 |
| cytology performed | #82 |
| tear lipid | #83 |
| expression corneal | #83 |
| complications lenses | #83 |
| dental college | #83 |
| patients staphylococcus aureus | #83 |
| data tacrolimus | #83 |
| earlier published data | #84 |
| correlation corneal | #84 |
| epithelium ocular | #84 |
| papillae | #84 |
| cytokines vegf | #84 |
| schirmer | #84 |
| alterations basal | #85 |
| patients dry | #85 |
| inhibitors tryptases | #85 |
| scleritis patients | #85 |
| hyperemia induced | #85 |
| treatment odds ratio | #85 |
| combined penetrating | #85 |
| 18 pg | #85 |
| human reverse | #85 |
| 5 grades | #85 |
| temperature patients | #85 |
| patients eyelid | #86 |
| daily outpatient | #86 |
| sligkv | #86 |
| pharmacologic intervention | #86 |
| inflammation eye | #86 |
| discharge evaluated | #86 |
| 284 years | #86 |
| edema scores | #86 |
| acuity accommodation | #86 |
| detection limit assay | #87 |
| tacrolimus young | #87 |
| confocal ophthalmic | #87 |
| tacrolimus reduced | #87 |
| daily weather conditions | #88 |
| tears | #88 |
| disease conjunctiva | #88 |
| post keratoplasty | #88 |
| sclera surgical | #88 |
| cells keratocytes | #88 |
| regulation muc5ac | #88 |
| assessment dry | #89 |
| seasonal perennial | #89 |
| tears visual | #89 |
| tryptase inhibitors | #89 |
| eyes 30 | #89 |
| findings severe | #89 |
| lower corneal | #90 |
| early ocular | #90 |
| months signs | #90 |
| temperature cornea | #90 |
| dressings chronic | #90 |
| tears adult | #90 |
| decrease corneal | #90 |
| cytocentrifuge preparations | #90 |
| glands microscopy | #90 |
| film breakup | #91 |
| lenses extended | #91 |
| laser cell | #92 |
| techniques trabeculectomy | #92 |
| eye corneal | #92 |
| procedures phacoemulsification | #92 |
| exposure japan | #92 |
| drug fibroblasts | #93 |
| 7 visit | #93 |
| solutions tears | #93 |
| eye cataract surgery | #93 |
| regulation muc1 | #93 |
| treatment noninfectious | #93 |
| stromal corneal | #93 |
| patients correlation | #93 |
| preschool conjunctiva | #93 |
| conjunctival specimens | #93 |
| 005 complications | #93 |
| tears administration | #93 |
| pgd2 crth2 | #94 |
| pollution weather | #94 |
| reaction physical | #94 |
| exposure exhaust | #94 |
| classification pathogenesis | #94 |
| case allergic | #94 |
| eosinophils patients | #95 |
| twentyeight eyes | #95 |
| eye higher | #95 |
| induced pgd2 | #95 |
| studies tears | #95 |
| relevant factor | #95 |
| study cyclosporine | #96 |
| staining fluorescein | #96 |
| 128 eyes | #96 |
| score objective | #96 |
| protein eosinophilia | #96 |
| higher eyes | #96 |
| 4 alterations | #97 |
| cells hel | #97 |
| treatment ecp | #97 |
| production pge2 | #97 |
| 1month treatment | #97 |
| eyes positive | #98 |
| meniscus patients | #98 |
| staining schirmer | #98 |
| eye tear | #98 |
| vdts | #98 |
| eyes study | #98 |
| surgery 6 months | #99 |
| solution improved | #99 |
| japan post | #99 |
| pseudophakic patients | #99 |
| equivalent 4 | #99 |
| 005 recurrence | #99 |
| cytology evaluation | #99 |
| management ocular | #99 |
| ointments tacrolimus | #100 |
| local pattern | #100 |
| postoperatively statistically | #100 |
| allergic atopic | #100 |
| confocal scanning | #100 |
| ulcer patient | #100 |
| corneal abnormalities | #100 |
| terminals contact | #100 |
| conjunctiva corneal | #100 |
| cells severity | #100 |
| pathogenesis atopic | #101 |
| fibroblasts 2 | #101 |
| eyes 10 | #101 |
| effects tranilast | #102 |
| disease classified | #102 |
| therapy conjunctival | #102 |
| pathogenesis allergic | #102 |
| severe atopic | #102 |
| agents conjunctivitis | #102 |
| keratolimbal allograft | #102 |
| prevalence dry | #103 |
| washing solution | #103 |
| chemotaxis experiments | #103 |
| mediated protease | #103 |
| subjective comfort | #103 |
| topical cyclosporine | #104 |
| topic premedication | #104 |
| patients bf | #104 |
| values vital | #104 |
| differences ocular | #104 |
| groups dry | #104 |
| events scores | #104 |
| tears young | #104 |
| allergic cytokines | #104 |
| syndrome epstein | #104 |
| role staphylococcal | #105 |
| conjunctival impression cytology | #105 |
| wearing contact | #105 |
| child conjunctival | #105 |
| inflammation diagnosis | #105 |
| baseline initiation | #105 |
| aged amnion | #105 |
| conjunctiva cornea | #106 |
| pressure keratoplasty | #106 |
| parameters ocular | #106 |
| adhesion fibroblasts | #106 |
| 14 eyes | #106 |
| microscopy evaluation | #106 |
| eotaxin1 | #107 |
| corneal keratocytes | #107 |
| patients ded | #107 |
| superficial punctate | #107 |
| induces chemotaxis | #108 |
| lipid layer | #108 |
| scores symptoms | #108 |
| topical tacrolimus | #108 |
| resins aged | #108 |
| acuity acrylic | #108 |
| film instability | #108 |
| conjunctiva | #108 |
| levels radioimmunoassay | #108 |
| dry mouth symptoms | #108 |
| 4 dry | #109 |
| effects dha | #109 |
| level tacrolimus | #109 |
| asian dust | #109 |
| il4 human | #109 |
| tear evaporation | #109 |
| corneal inflammatory | #109 |
| increased evaporation | #110 |
| lacrimal salivary | #110 |
| steroids administration | #110 |
| conjunctival epithelium | #110 |
| eyes 9 | #110 |
| controls inflammatory | #110 |
| japanese guidelines | #110 |
| dysfunction mgd | #110 |
| topical instillation | #111 |
| severity markers | #111 |
| eye camera | #112 |
| vcam1 antibody | #112 |
| pcr rsv | #113 |
| strabismus surgery | #113 |
| papillary conjunctivitis | #113 |
| solutions platelet | #113 |
| dibenzoxepins | #113 |
| anterior segment inflammation | #113 |
| grading scores | #114 |
| eye irritation | #114 |
| lesions atopic | #114 |
| layer patients | #114 |
| incision cataract | #114 |
| diagnosed allergic | #114 |
| allergic eye | #115 |
| 13 eyes | #115 |
| seconds 0001 | #115 |
| cholinergic treatment | #115 |
| findings severity | #115 |
| goblet cell density | #115 |
| sjögrens syndrome patients | #115 |
| conjunctival cell | #115 |
| male mucin | #115 |
| selective histamine | #116 |
| edition revised | #116 |
| metaplasia mucins | #117 |
| viscosupplements aged | #117 |
| patients seasonal | #117 |
| cooling increased | #117 |
| asia dust | #117 |
| ophthalmology prevalence | #117 |
| samples stained | #117 |
| molecule1 interleukin4 | #118 |
| generation pge2 | #118 |
| immunologic receptors prostaglandin | #118 |
| sag genes | #118 |
| effects docosahexaenoic | #118 |
| skin elasticity | #119 |
| 39 mmhg | #119 |
| iop observed | #119 |
| chemotaxis induced | #119 |
| topical steroids | #119 |
| revealed higher | #119 |
| week 005 | #119 |
| acuity distance | #119 |
| syndromes epithelium | #120 |
| matter prevalence | #120 |
| soft lenses | #121 |
| mitomycinc mmc | #121 |
| levels histamine | #121 |
| distance corrected | #121 |
| mitomycin ophthalmic | #121 |
| chronic allergic | #122 |
| collagen conjunctiva | #123 |
| artificial tear | #123 |
| male ointments | #123 |
| titers ebv | #123 |
| adult conjunctiva | #123 |
| eosinophils cell | #124 |
| area corneal | #124 |
| activity corneal | #125 |
| conjunctival tissues | #125 |
| damage severe | #126 |
| proteaseactivated receptor2 | #126 |
| month reduced | #126 |
| 05ng | #127 |
| patients atopic | #127 |
| subjects vivo | #127 |
| nerves studied | #127 |
| gamma increase | #128 |
| soft contact lenses | #128 |
| 9 genes | #128 |
| 361 ± | #129 |
| combination steroids | #129 |
| fibroblast viability | #129 |
| acds | #129 |
| elisa levels | #129 |
| patients insignificant | #130 |
| fva | #130 |
| functional visual | #130 |
| disease cornea | #131 |
| antigen hladr | #131 |
| resection severe | #132 |
| 5ac | #132 |
| eye drop | #132 |
| management allergic | #132 |
| cataract phacoemulsification | #132 |
| eyes fluorescein | #132 |
| treated tacrolimus | #133 |
| proteins mucin | #133 |
| gene transcription levels | #133 |
| skin water | #133 |
| 19 normal subjects | #133 |
| keratoplasty adult | #133 |
| acrylic iol | #134 |
| density negative | #134 |
| normal conjunctival | #134 |
| surface examination | #134 |
| pcr hla | #134 |
| specimens vivo | #135 |
| solutions phacoemulsification | #135 |
| stress status | #136 |
| iop treatment | #136 |
| eosinophil adhesion | #137 |
| ophthalmological dry | #137 |
| dry eye patients | #137 |
| severity 10 | #137 |
| ocular surface | #137 |
| antiallergic properties | #137 |
| iol groups | #138 |
| eosinophil cationic protein | #138 |
| asian dust storms | #138 |
| authors technique | #139 |
| allergic dogs | #139 |
| protein ecp | #139 |
| ratio remission | #139 |
| suppressed pretreatment | #140 |
| inflammation prostaglandin | #141 |
| allergic patients | #141 |
| aminobenzoates anti | #141 |
| improvements symptom | #142 |
| interleukin1 interleukin13 | #142 |
| findings upper | #142 |
| olopatadine hydrochloride | #143 |
| combination rapid | #143 |
| studies scleritis | #144 |
| 52 mmhg | #144 |
| determine central | #144 |
| cornea cyclosporine | #144 |
| recordable | #145 |
| eye syndromes | #145 |
| specimens patient | #145 |
| symptoms ocular | #145 |
| findings adolescent | #146 |
| human conjunctiva | #146 |
| eye clinical | #146 |
| virus pathogen | #146 |
| fibroblasts alpha | #146 |
| schiff reaction | #146 |
| underwent evaluation | #146 |
| reticular basement membrane | #146 |
| required type | #147 |
| dscg | #147 |
| 263 years | #147 |
| impression cytology | #147 |
| hne 4 | #147 |
| diagnosis atopic | #147 |
| 0001 corneal | #148 |
| increased goblet | #148 |
| dynamic visual acuity | #148 |
| ulcer drug | #148 |
| quantitative evaluation | #149 |
| suspension based | #149 |
| patients allergic | #149 |
| intraocular lens iol | #149 |
| fibroblasts production | #149 |
| cationic protein | #149 |
| concentration tacrolimus | #149 |
| japan phenotype | #149 |
| japanese cedar pollen | #150 |
| pyrimidinones treatment | #150 |
| inflammatory cells | #150 |
| controls performed | #151 |
| inflammation reduction | #151 |
| par2 reverse | #152 |
| tacrolimus treated | #152 |
| postoperative secondary | #152 |
| induced eotaxin | #153 |
| increased fibroblasts | #153 |
| artificial tears | #153 |
| symptoms objective | #153 |
| 28 surgery | #153 |
| eyes 11 | #153 |
| concentrations il4 | #154 |
| inflammation ocular | #155 |
| male mitomycin | #155 |
| grade effects | #155 |
| alcon | #156 |
| association pm25 | #156 |
| chemokine expression | #156 |
| eyelids female | #156 |
| greater inflammation | #157 |
| analysis prostaglandin | #157 |
| inflammatory ocular | #157 |
| ointments skin | #157 |
| pcr increase | #157 |
| values improved | #157 |
| rates untreated | #157 |
| lipid infiltration | #157 |
| surface status | #158 |
| acuities | #158 |
| japan included | #158 |
| trial tacrolimus | #158 |
| 3 boys | #159 |
| weeks adverse | #159 |
| immunological characteristics | #159 |
| study inflammation | #160 |
| muc16 | #161 |
| chemokines production | #161 |
| elevation study | #161 |
| acid schiff | #161 |
| mucin 5ac | #161 |
| 28 female | #161 |
| thirtysix eyes | #161 |
| male meibomian | #162 |
| 326 years | #162 |
| surgery topical | #162 |
| bromobenzenes | #162 |
| distance visual acuity | #162 |
| visit 7 | #163 |
| twentynine eyes | #163 |
| oxidative stress status | #163 |
| olopatadine | #163 |
| efficacy tacrolimus | #163 |
| il1beta il2 | #163 |
| prevalence ocular | #163 |
| studied 21 | #163 |
| patients topical | #164 |
| 30ng | #164 |
| soft contact | #164 |
| 002 treatment | #164 |
| steroid anti | #164 |
| spt positive | #164 |
| purpose reported | #164 |
| biological dressings | #165 |
| production prostaglandin | #165 |
| pgd2 induced | #166 |
| cytometry hla | #166 |
| fluorescein humans | #166 |
| eosinophils higher | #167 |
| cytokines allergic | #167 |
| tacrolimus ointment | #167 |
| males 5 | #168 |
| ulcers erosions | #168 |
| seldi | #169 |
| treating refractory | #169 |
| studies tacrolimus | #169 |
| 12 males | #169 |
| patients postsurgical | #169 |
| eotaxin chemokine | #169 |
| local allergic | #169 |
| steroidal blotting | #169 |
| expression chemokines | #170 |
| conjunctiva conjunctival | #171 |
| management enzyme | #171 |
| status inflammation | #171 |
| subbasal nerve | #172 |
| fibroblasts fibroblast | #173 |
| palisades | #173 |
| subjective symptoms | #174 |
| distance acuity | #174 |
| standard conventional | #174 |
| slit lamp | #174 |
| status oxidative | #174 |
| pcr flow | #174 |
| vivo confocal | #174 |
| postkeratoplasty | #175 |
| 34 eyes | #175 |
| evaluated symptoms | #176 |
| homologous molecule | #176 |
| dust extract | #177 |
| aldehydes biomarkers | #177 |
| subbasal | #177 |
| study longterm outcomes | #177 |
| treatment corneal | #177 |
| endophthalmitis female | #178 |
| reduction intraocular pressure | #178 |
| mild 2 | #178 |
| tryptase | #178 |
| acrysof | #178 |
| strabismus adolescent | #178 |
| risk ocular | #179 |
| chemokine genes | #179 |
| 4 female | #180 |
| myopic regression | #180 |
| japan young adult | #180 |
| migration eosinophils | #180 |
| dyes follow | #180 |
| compared eye | #180 |
| ceramides child | #180 |
| lipid study | #181 |
| normal control patients | #181 |
| cutometer | #181 |
| lipoproteins micafungin | #183 |
| blepharitis | #183 |
| serum il4 | #183 |
| male radioallergosorbent | #184 |
| human lymphocyte antigen | #185 |
| mucin4 mucins | #185 |
| igg virus | #185 |
| examined parameters | #186 |
| nerve prospective | #186 |
| therapy corneal | #186 |
| par2 mrna | #187 |
| efficacy topical | #187 |
| corneal fibroblasts | #187 |
| atopic eosinophils | #187 |
| drug fibroblasts humans | #187 |
| suspensions administration | #187 |
| il13 increased | #188 |
| eye symptoms | #188 |
| corneal sensitivity | #188 |
| 19 eyes | #188 |
| production stromal | #189 |
| sensitivity regulation | #189 |
| allergic cross | #189 |
| seconds patients | #189 |
| levels 33 | #190 |
| infiltrating eosinophils | #191 |
| tear break | #191 |
| assisted infrared | #191 |
| effects diesel | #191 |
| improvement subjective | #192 |
| allergic rhinoconjunctivitis | #193 |
| therapeutic study | #193 |
| controls vivo | #193 |
| 26 eyes | #194 |
| reactivation epstein | #195 |
| expression rantes | #195 |
| fibroblasts inhibited | #195 |
| rigid gas | #196 |
| female histamine | #196 |
| treatment topical | #197 |
| 80 allergens | #197 |
| tear film stability | #197 |
| interleukin4 production | #197 |
| eyes 21 | #197 |
| methods primary | #197 |
| combination topical | #198 |
| 28 eyes | #198 |
| tears time | #198 |
| elisa performed | #198 |
| effects topical | #199 |
| pollen prospective | #199 |
| preservative free | #201 |
| perennial allergic | #201 |
| photorefractive keratectomy | #201 |
| mcp1 ip10 | #201 |
| pollen allergic | #201 |
| hypersensitivity interleukin13 | #202 |
| unit density | #202 |
| receptor homologous | #202 |
| rsv infected | #202 |
| eosinophils neutrophils | #203 |
| ova alum | #204 |
| pge2 human | #204 |
| vcam1 icam1 | #204 |
| grade scale | #204 |
| differences iop | #204 |
| eyes 005 | #205 |
| inflammatory allergic | #205 |
| disease acd | #206 |
| disease dry | #206 |
| eyes cataract | #206 |
| minutes 8 | #206 |
| time tbut | #206 |
| glands middle | #207 |
| ecp levels | #207 |
| crth2 | #207 |
| pressure lens | #207 |
| formation giant | #207 |
| count cornea | #207 |
| tears aged | #208 |
| size contact | #208 |
| fluorescein fluorescent | #208 |
| mammalian milk | #208 |
| analysis pm25 | #209 |
| uncorrected corrected | #209 |
| treatment allergic | #210 |
| human allergic | #210 |
| month reduction | #210 |
| refractory conventional | #211 |
| oct diagnosis | #211 |
| antiallergic drug | #211 |
| iol patients | #212 |
| combination tests | #212 |
| tacrolimus combination | #212 |
| inflammation injection | #212 |
| conjunctiva eye | #213 |
| treated refractory | #213 |
| chamber anti | #213 |
| steroids treatment | #214 |
| muc5ac | #214 |
| alpha il4 | #215 |
| ige higher | #216 |
| conjunctival goblet | #217 |
| allergic agents | #217 |
| worse eyes | #218 |
| lens purpose | #218 |
| nuclear cataract | #219 |
| expressions higher | #219 |
| tranilast | #220 |
| metabolism lysine | #220 |
| conjunctival biopsy | #220 |
| august october | #220 |
| conjunctivitis acute | #221 |
| findings inflammation | #221 |
| cells crth2 | #222 |
| twentyfour eyes | #222 |
| combined therapy | #222 |
| samples correlated | #222 |
| diseases dry | #222 |
| level ambient | #222 |
| iop corneal | #224 |
| 26 control subjects | #224 |
| sensitivity measurements | #224 |
| symptoms short | #224 |
| allergic drug | #225 |
| patients eye | #226 |
| 17 eyes | #227 |
| eyes adult | #228 |
| corneal clarity | #228 |
| treatment 3 months | #228 |
| itching | #229 |
| followup cases | #229 |
| treatment superior | #230 |
| corrected distance | #230 |
| eye signs | #230 |
| exhaust particles | #231 |
| activity eosinophils | #231 |
| 30 eyes | #231 |
| scleral flap | #232 |
| events initiation | #232 |
| examined level | #232 |
| alpha defensin | #232 |
| 791 patients | #233 |
| dye staining | #233 |
| cyclosporine treatment | #233 |
| anti allergic | #233 |
| concomitantly administered | #233 |
| proteinchip | #233 |
| 644 years | #234 |
| cultured eosinophils | #235 |
| examined production | #235 |
| corneal disease | #236 |
| specimens patients | #236 |
| quantitatively evaluate | #236 |
| term topical | #237 |
| gamma transcripts | #237 |
| topical steroid | #238 |
| diagnostic abilities | #240 |
| proliferative lesions | #240 |
| studied subjects | #240 |
| tool quantitative | #240 |
| eyes ocular | #241 |
| bf patients | #241 |
| cell chemotactic | #242 |
| surface lipid | #242 |
| cromolyn sodium | #242 |
| common ocular | #245 |
| performed higher | #245 |
| specular microscopy | #246 |
| subjects males | #247 |
| equivalent 2 | #247 |
| eye drops | #247 |
| specificity cutoff | #248 |
| chemosis | #248 |
| failure visual | #250 |
| labeling intercellular | #251 |
| response prostaglandin | #251 |
| syndrome tears | #252 |
| males 13 | #252 |
| seasonal allergic | #252 |
| leukocyte child | #252 |
| subjective objective | #252 |
| levels tacrolimus | #253 |
| topical oral | #253 |
| improved vision | #255 |
| corneal female | #255 |
| muc | #255 |
| rantes expression | #256 |
| stability positive | #256 |
| dexamethasone inhibition | #256 |
| disease corneal | #257 |
| treating severe | #257 |
| eosinophil chemotaxis | #258 |
| tear | #259 |
| questionnaire objective | #259 |
| eyes control | #260 |
| role histamine | #260 |
| month treatment | #260 |
| additional medications | #260 |
| eosinophil infiltration | #260 |
| human transcription | #261 |
| expression rsv | #261 |
| smaller normal | #262 |
| h1 antagonist | #262 |
| 1 month treatment | #264 |
| immunohistochemistry increased | #264 |
| aged mucin | #264 |
| severity adverse | #264 |
| steroid induced | #265 |
| keratoplasty pkp | #265 |
| controls p0001 | #266 |
| eyelid diseases | #266 |
| data weekly | #267 |
| signs blood | #267 |
| treatment atopic | #268 |
| respiratory syncytial virus | #268 |
| microscopy negative | #268 |
| patients sjögren syndrome | #268 |
| studied production | #268 |
| sodium drug | #269 |
| aged aldehyde | #270 |
| h1 histamine | #270 |
| computer terminals | #270 |
| dry eye symptoms | #271 |
| prevalence allergic | #272 |
| aldose reductase inhibitor | #273 |
| 13 males | #273 |
| improved visual acuity | #273 |
| epithelium endothelium | #274 |
| studies stevens | #274 |
| combination eosinophils | #274 |
| concentration quantitative | #274 |
| meibomian gland dysfunction | #275 |
| patients sjögren | #277 |
| tear breakup time | #277 |
| meibomian gland | #277 |
| tbut | #278 |
| individuals pcr | #278 |
| grading score | #278 |
| 13 females | #279 |
| eyes 14 | #279 |
| bloodaqueous barrier | #279 |
| 0001 diagnosis | #279 |
| multifunctional glycoprotein | #280 |
| interleukin il4 | #280 |
| 10 seconds | #281 |
| required provide | #281 |
| cautery | #282 |
| expressed th2 | #282 |
| disease purpose | #282 |
| ige positive | #284 |
| gland dysfunction | #284 |
| contralateral eye | #285 |
| amniotic membrane | #285 |
| seasons adolescent | #286 |
| atopic | #286 |
| th2 cytokines | #287 |
| layer adult | #288 |
| cases refractory | #288 |
| adult alkylating | #289 |
| study tacrolimus | #289 |
| eyedrops | #291 |
| entericcoated | #291 |
| water child | #292 |
| iop glaucoma | #293 |
| new antifungal | #294 |
| treatment 01 | #294 |
| exponential equation | #294 |
| serum periostin | #295 |
| levels ige | #295 |
| single therapy | #295 |
| surgery statistically | #297 |
| hyperemia | #297 |
| seventy eyes | #299 |
| severity diagnosis | #300 |
| ccl11 chemokine | #300 |
| rose bengal | #300 |
| pkp | #301 |
| benzalkonium chloride | #301 |
| morphologic alterations | #302 |
| assessed based | #303 |
| cobblestone | #303 |
| moderate 3 | #303 |
| photophobia | #304 |
| scanning laser | #304 |
| scores worse | #305 |
| operation patient | #305 |
| initiation treatment | #305 |
| piperidines treatment | #306 |
| eczema severity | #306 |
| assessed 4 | #307 |
| membrane patch | #307 |
| gel application | #308 |
| 10 normal subjects | #309 |
| evaluation groups | #309 |
| interleukin13 interleukin2 | #309 |
| compared simple | #310 |
| comfort level | #310 |
| inflammatory cell | #310 |
| 12 eyes | #311 |
| treatment seasonal | #311 |
| cytology specimens | #311 |
| regard age | #311 |
| slitlamp examination | #311 |
| 7 eyes | #312 |
| molecules chronic | #313 |
| eye adult | #315 |
| aged staining | #315 |
| 19 normal | #316 |
| child corneal | #316 |
| cells cornea | #317 |
| interferometry light | #317 |
| analysis glaucoma | #318 |
| values lower | #319 |
| prospective singlearm study | #320 |
| fluorophotometry | #320 |
| dermatitis clinical | #320 |
| cells chemotaxis | #321 |
| il8 rantes | #321 |
| ulcers | #323 |
| bilateral cataracts | #323 |
| pollen allergen | #324 |
| agreement weighted | #324 |
| 15 30 minutes | #325 |
| eyes 19 | #325 |
| 095 ± | #326 |
| icam1 vcam1 expression | #326 |
| surgery diabetic | #327 |
| chemokine concentrations | #327 |
| transplantation corneal | #328 |
| icam1 antibody | #329 |
| expression goblet | #329 |
| insensible | #330 |
| treatment 2 weeks | #331 |
| pressure ocular | #331 |
| receptors il2r | #332 |
| dry eye disease | #332 |
| leukocyte coculture | #333 |
| eye treated | #335 |
| cornea diagnostic | #335 |
| values daily | #335 |
| proprietary | #336 |
| corneal epithelial | #337 |
| male staphylococcal | #337 |
| 27 eyes | #337 |
| signs clinical | #339 |
| daily wear | #339 |
| eyes 27 | #341 |
| levels epithelial | #341 |
| methods eyes | #342 |
| asthenopia | #343 |
| illness tacrolimus | #344 |
| limbus | #346 |
| measurements treatment | #347 |
| corneal infection | #347 |
| expression eosinophils | #348 |
| induced elevation | #348 |
| eyes 13 | #348 |
| test values | #350 |
| surgery eye | #350 |
| contrast visual | #352 |
| surface diseases | #352 |
| iop elevation | #353 |
| expression allergic | #354 |
| weekly average | #354 |
| incidence allergic | #355 |
| temperature infrared | #355 |
| choroidal detachment | #356 |
| examination serum | #356 |
| tear film | #357 |
| patients allergy | #357 |
| eyes 8 | #358 |
| local cytokine | #358 |
| tacrolimus tumor | #359 |
| months conventional | #359 |
| difference efficacy | #361 |
| subjects 13 | #361 |
| agents benzophenones | #362 |
| messenger blotting | #363 |
| aureus patients | #363 |
| injections lidocaine | #364 |
| treatment ocular | #368 |
| plant pollen | #368 |
| function laser | #368 |
| studies sclera | #368 |
| corneae male | #369 |
| mucin1 mucin2 | #370 |
| postoperative adhesion | #370 |
| eyes 17 | #370 |
| systemic control | #371 |
| inhibitors epithelium | #372 |
| cryptomeria japonica | #372 |
| sixteen eyes | #373 |
| micafungin middle | #374 |
| periodic acid schiff | #374 |
| assessment severe | #375 |
| cornea female | #375 |
| improvement local | #375 |
| extraction cell | #376 |
| retina tomograph | #376 |
| higher human | #377 |
| 4 lower | #377 |
| levels atopic | #377 |
| phacoemulsification prospective | #377 |
| 10 normal | #377 |
| count child | #378 |
| treatment eyes | #378 |
| tarsal | #378 |
| mitomycin | #380 |
| stimulation tnf | #380 |
| cornea eye | #381 |
| corneal inflammation | #381 |
| negative serum | #382 |
| inflammation epithelial | #383 |
| pollinosis | #383 |
| gas permeable | #384 |
| examinations including | #384 |
| vivo corneal | #385 |
| corneal epithelial cells | #386 |
| ocular diseases | #386 |
| limit assay | #388 |
| surgery 13 | #388 |
| decrease inflammatory | #388 |
| surface alterations | #388 |
| cells vehicle | #389 |
| healing adult | #389 |
| sde | #390 |
| severity incidence | #390 |
| antiallergic | #391 |
| patients proteins | #391 |
| breakup time | #393 |
| immunohistochemistry tests | #394 |
| 44 eyes | #395 |
| applied 5 | #395 |
| chronic ocular | #395 |
| opacity corneal | #396 |
| relative percentages | #396 |
| techniques interleukin4 | #396 |
| apparatus lacrimal | #397 |
| expression lower | #397 |
| increased understanding | #398 |
| pressure elevation | #399 |
| ocular surface disease | #399 |
| remission based | #400 |
| declaration helsinki | #400 |
| eyes severe | #401 |
| modified boyden | #401 |
| rays male | #402 |
| sedating humans | #403 |
| vogt | #404 |
| cells allergic | #404 |
| weather air | #404 |
| measurements oct | #404 |
| prospective controlled study | #405 |
| patients epithelial | #406 |
| reproducibility surface | #406 |
| 137 years | #407 |
| improved diagnosis | #407 |
| serum total ige | #407 |
| postoperative aged | #408 |
| activated fibroblasts | #409 |
| heidelberg retina tomograph | #410 |
| confocal | #412 |
| specific total | #412 |
| acids fibroblasts | #412 |
| eyes 15 | #412 |
| counts 1 | #413 |
| 3 months treatment | #413 |
| allergic reaction | #413 |
| keratocytes | #414 |
| limbal | #416 |
| postoperative inflammation | #416 |
| penetrating keratoplasty | #418 |
| central cornea | #418 |
| mucin4 | #419 |
| patients comfort | #419 |
| chemokine ccl11 | #419 |
| speed resolution | #419 |
| sjögren syndrome | #420 |
| ophthalmologist | #420 |
| lacrimal gland | #422 |
| 20 normal controls | #424 |
| clinical observation | #425 |
| 40 minutes | #425 |
| trabeculectomy visual | #430 |
| production 4 | #430 |
| staining score | #431 |
| rhinoconjunctivitis | #431 |
| 0 normal | #433 |
| subjects atopic | #434 |
| cedrus | #437 |
| performed immunohistochemistry | #437 |
| 5 women | #438 |
| methods eye | #438 |
| regulation eye | #438 |
| commercial tests | #439 |
| subjects studied | #440 |
| interleukin4 il4 | #440 |
| foldable | #440 |
| regulation chemokine | #441 |
| fluorescein dye | #441 |
| landolt | #441 |
| vmr | #441 |
| females normal | #442 |
| anti vcam1 | #442 |
| adult aldehydes | #442 |
| 17 males | #444 |
| male mucin1 | #444 |
| patients combined therapy | #445 |
| 39 consecutive patients | #447 |
| air pollution data | #448 |
| dogs dust | #448 |
| male 4 | #450 |
| 30 serum | #450 |
| eye eyes | #451 |
| keratoplasty | #452 |
| wash | #452 |
| ketotifen | #453 |
| antagonists sedating | #453 |
| versus vehicle | #453 |
| surface disorder | #454 |
| normal patients | #454 |
| response allergens | #454 |
| vivo confocal microscopy | #454 |
| ophthalmic nerve | #455 |
| production clearance | #455 |
| 8 genes | #455 |
| water evaporation | #455 |
| humans keratoplasty | #456 |
| agonists pilocarpine | #456 |
| outpatient visits | #457 |
| ocular risk | #457 |
| amnion cell | #457 |
| normal controls patients | #457 |
| checker | #459 |
| oct study | #460 |
| distance visual | #461 |
| greatest improvements | #461 |
| test evaluation | #462 |
| keratoplasty penetrating | #462 |
| hel | #466 |
| fibroblasts tgf | #467 |
| unpaired ttest | #467 |
| study pcr | #468 |
| examination diagnosis | #469 |
| background atopic | #469 |
| major sources | #470 |
| markers severity | #473 |
| allergy adult | #473 |
| metry | #475 |
| hladr expression | #476 |
| diagnosis rate | #476 |
| 13 mmhg | #478 |
| fibroblasts primary | #478 |
| pollen seasons | #478 |
| newly formed vessels | #480 |
| reduce clinical | #480 |
| height measurement | #480 |
| subjects eyes | #481 |
| interleukin 13 | #482 |
| examined prospective | #482 |
| crystalline lens implantation | #485 |
| accommodating | #488 |
| 21 eyes | #488 |
| induced 15 | #489 |
| myopia photorefractive | #490 |
| shortterm study | #490 |
| disodium cromoglycate | #493 |
| acuity intraocular | #495 |
| prolonged inflammation | #495 |
| ebv reactivation | #495 |
| months eyes | #498 |
| corneal | #498 |
| exposure diesel | #499 |
| stain positive | #499 |
| il2 tumor | #499 |
| lens iol | #500 |
| silicone hydrogel | #500 |
| infections viral | #501 |
| symptoms efficacy | #501 |
| pge2 cox2 | #502 |
| studies status | #502 |
| treatment eye | #502 |
| heidelberg retina | #503 |
| 42 eyes | #504 |
| 2 daily | #505 |
| eye position | #505 |
| correlate severity | #506 |
| airborne particulate matter | #506 |
| inflammatory status | #506 |
| penetrating male | #507 |
| induced ocular | #509 |
| aldose reductase | #509 |
| 1 mild | #511 |
| cats child | #512 |
| treatment visual | #514 |
| topical | #516 |
| 45 subjects | #516 |
| disposable equipment | #517 |
| male water | #519 |
| observed baseline | #519 |
| inhibition production | #519 |
| groups duration | #520 |
| lipopeptides lipoproteins | #520 |
| chemoattractant receptor | #522 |
| 01 | #522 |
| metaregression analysis | #523 |
| 10 normal volunteers | #524 |
| infection rsv | #524 |
| dinoprostone epithelial | #525 |
| studies trabeculectomy | #525 |
| studies cornea | #527 |
| trabeculectomy | #527 |
| density basal | #528 |
| giemsa staining | #528 |
| itchy | #531 |
| rhodanine | #531 |
| ocular symptoms | #535 |
| serum antigen | #535 |
| 44yearold | #536 |
| purpose case | #537 |
| total hydrocarbons | #538 |
| patients cataract | #538 |
| dependent migration | #539 |
| sac | #539 |
| placebo tablets | #540 |
| capsular bag | #540 |
| visit 6 | #541 |
| 80 anterior | #541 |
| cases flow | #542 |
| administration topical | #542 |
| 20 normal | #543 |
| infrared radiation | #543 |
| 6 male | #544 |
| production cultured | #546 |
| ebv nuclear antigen | #546 |
| time improved | #547 |
| pollution allergens | #549 |
| periodic acid | #549 |
| film layer | #550 |
| prospective comparative study | #550 |
| il‐4 | #552 |
| cryptomeria | #552 |
| disease complicated | #553 |
| effects cooling | #553 |
| engorgement | #554 |
| disease ded | #555 |
| genechip | #555 |
| fibroblasts response | #555 |
| setting department | #556 |
| noninfected cells | #557 |
| density assessed | #558 |
| transplantation combined | #558 |
| diesel exhaust particles | #559 |
| methods thirty | #559 |
| eyes iop | #560 |
| differentiation inflammatory | #560 |
| ocular infections | #560 |
| eyes 24 | #562 |
| laser trabeculoplasty | #562 |
| positive 30 | #563 |
| 16 age | #569 |
| count corneal | #569 |
| cultured corneal | #570 |
| levels il4 | #570 |
| meibomian | #572 |
| female humans specificity | #576 |
| allergen challenge | #577 |
| corneal diseases | #578 |
| 4 mrna | #580 |
| iop eyes | #580 |
| fibrosis fluorescent | #582 |
| apparatus male | #582 |
| lesions normal | #582 |
| increase vegf | #584 |
| department ophthalmology | #584 |
| tnfalpha stimulation | #584 |
| symptoms scores | #588 |
| patients csa | #589 |
| induced 4 | #589 |
| intraocular male | #589 |
| female humans allergic | #589 |
| hladr antigen | #589 |
| corneal epithelium | #589 |
| study lipid | #590 |
| diseases regulation | #591 |
| icam1 vcam1 | #592 |
| cytological techniques | #593 |
| observed real | #595 |
| findings evaluated | #597 |
| assay eye | #597 |
| epithelium corneal | #598 |
| cells chemokine | #599 |
| diesel exhaust | #602 |
| cornea epithelium | #603 |
| mrna tgf | #604 |
| thermometer | #605 |
| grading scale | #606 |
| inflammation status | #609 |
| topical adult | #609 |
| corneal nerves | #611 |
| thermography | #611 |
| eosinophils epithelial | #612 |
| fluorescent dyes humans | #613 |
| synergic | #614 |
| patients complained | #615 |
| antagonists humans | #615 |
| cells oligopeptides | #616 |
| diagnosis type | #616 |
| grades 0 | #617 |
| ocular allergy | #617 |
| flaps suture | #618 |
| subjects conclusion | #621 |
| il4 | #623 |
| glaucoma medications | #625 |
| years studied | #625 |
| lamp examination | #625 |
| ophthalmologists | #626 |
| occlusion treatment | #628 |
| micafungin | #635 |
| patients tacrolimus | #636 |
| redness | #636 |
| burning sensation | #636 |
| corneal haze | #636 |
| total immunoglobulin | #638 |
| contact lenses | #639 |
| eosinophils | #639 |
| based severity | #639 |
| male rhinitis | #640 |
| 511 patients | #640 |
| 11 eyes | #641 |
| development allergic | #641 |
| performed modified | #643 |
| months 01 | #643 |
| symptoms signs | #643 |
| observed follow | #644 |
| mellitus double | #645 |
| fibrosis actins | #645 |
| patients healthy volunteers | #650 |
| 2 females | #651 |
| viscosupplements | #651 |
| expression administration | #651 |
| analysis existence | #654 |
| eosinophils flow | #654 |
| diseases methods | #656 |
| lacrimal | #657 |
| comfortable | #657 |
| patients elisa | #660 |
| 96well plate | #661 |
| nerve density | #661 |
| chamber technique | #662 |
| treatment 0001 | #664 |
| lens wearers | #664 |
| acuity measured | #665 |
| molecule1 cell | #668 |
| 10 age | #669 |
| damage scores | #669 |
| viruses acute | #669 |
| stimulation rna | #672 |
| cedar | #672 |
| 11 males | #673 |
| humans lacrimal | #673 |
| scleritis | #677 |
| levels correlation | #678 |
| administration ophthalmic | #680 |
| test methods | #681 |
| adherence anti | #681 |
| antibody negative | #682 |
| chemokine gene | #683 |
| stainings | #684 |
| fibronectin cell | #684 |
| single visit | #685 |
| goblet | #686 |
| cells collected | #688 |
| differential diagnosis patients | #689 |
| visual acuity patients | #690 |
| atopic female humans | #694 |
| cells eye | #694 |
| 1 test | #695 |
| early antigen | #697 |
| inhibition expression | #697 |
| levels detection | #700 |
| objective assessments | #700 |
| cromolyn | #700 |
| intraocular inflammation | #703 |
| eyelid | #704 |
| labeling surface | #705 |
| antineoplastic child | #707 |
| participants eyes | #709 |
| pain baseline | #711 |
| allergens child | #712 |
| 1 month | #715 |
| fibroblasts flow | #715 |
| major characteristic | #717 |
| 5 eyes | #718 |
| key cells | #718 |
| dibenzazepines | #719 |
| preventing recurrence | #721 |
| production vascular | #722 |
| 32 eyes | #724 |
| 088 ± | #724 |
| promising treatment strategy | #725 |
| squamous metaplasia | #729 |
| followup treatment | #730 |
| aged ophthalmology | #730 |
| 11 male | #730 |
| cytology patients | #731 |
| eyes underwent | #733 |
| pollution data | #735 |
| suppressive effects | #736 |
| symptoms 5 | #737 |
| reductase inhibitor | #737 |
| intraocular lens | #740 |
| keratectomy | #741 |
| density compared | #741 |
| expression real | #744 |
| blood eosinophils | #746 |
| definition classification | #746 |
| unpaired test | #746 |
| inflammation lipid | #748 |
| purpose hypothesis | #749 |
| cornea corneal | #751 |
| daily weather | #751 |
| interleukin13 male | #752 |
| fibroblasts cultured | #754 |
| eyes 6 | #758 |
| iol implantation | #759 |
| follow cases | #759 |
| allergens anti | #762 |
| trabeculectomy treatment | #763 |
| intraocular lens implantation | #763 |
| topical aged | #763 |
| 148 years | #764 |
| drugs primary | #765 |
| aged chemokine | #766 |
| oligopeptides rna | #769 |
| pathogenesis severe | #769 |
| measurements improved | #772 |
| pge2 production | #775 |
| eotaxin | #776 |
| cells adolescent | #782 |
| levels prostaglandin | #783 |
| role allergic | #783 |
| limbus corneae | #784 |
| fluorescein fluoresceins | #784 |
| blinking | #785 |
| purpose analyze | #785 |
| treatment 1 | #785 |
| elevated levels | #789 |
| allergic disease | #790 |
| lenses intraocular | #792 |
| eyes normal | #792 |
| tacrolimus | #793 |
| increased epithelial | #793 |
| techniques laminin | #793 |
| ocular inflammation | #794 |
| 4 hne | #794 |
| months visual | #798 |
| treatment p0001 | #800 |
| positive linear | #801 |
| report efficacy | #801 |
| radioallergosorbent | #802 |
| excimer male | #804 |
| cells western | #806 |
| receptors ccr3 | #813 |
| mucin | #813 |
| 21 individuals | #814 |
| brush | #816 |
| acuity adolescent | #817 |
| biomicroscopy | #819 |
| aged cell | #820 |
| concentration dose | #820 |
| interleukin4 | #821 |
| cells eosinophils | #821 |
| phenotype practice | #822 |
| temperature case | #825 |
| year adolescent | #831 |
| lymphocytes compared | #834 |
| preoperative level | #834 |
| surgical outcome | #835 |
| cases follow | #835 |
| pachymetry | #840 |
| individuals patients | #841 |
| patients operation | #841 |
| implantation intraocular | #842 |
| symptoms improved | #843 |
| ocular adolescent | #843 |
| elevated iop | #845 |
| new surgical technique | #845 |
| 2 weeks treatment | #848 |
| exhaust | #848 |
| levels air | #848 |
| loss insensible | #851 |
| fluorescein | #853 |
| cell area | #855 |
| purpose prospectively | #855 |
| 10 eyes | #858 |
| methane hydrocarbons | #860 |
| myopic eyes | #861 |
| inhibitors diclofenac | #861 |
| thiazolidines | #865 |
| histamine h1 | #865 |
| thirteen cases | #866 |
| patients ocular | #867 |
| test kits | #868 |
| serum antibody titers | #872 |
| patients eyes | #874 |
| 01 compared | #874 |
| dry eyes | #876 |
| mitomycinc | #878 |
| syndrome sjs | #879 |
| h1 antagonists | #880 |
| evaluation early | #880 |
| benzamidine | #880 |
| patient comfort | #881 |
| assessing efficacy | #882 |
| cells contributes | #882 |
| diseases background | #883 |
| study eye | #886 |
| patients condition | #887 |
| bleb | #887 |
| specular | #890 |
| 114 years | #894 |
| respiratory syncytial | #894 |
| age eye | #895 |
| noncomparative | #897 |
| pain inflammation | #901 |
| ocular | #902 |
| levels pm25 | #903 |
| 20 eyes | #904 |
| benzophenones | #905 |
| decreased baseline | #905 |
| circulating autoantibodies | #907 |
| clinical signs | #910 |
| lacrimal duct | #911 |
| examined pcr | #911 |
| aureus young | #912 |
| gauze | #917 |
| corneae | #919 |
| sjögren | #920 |
| immunoglobulin immunosuppressive | #921 |
| 10 females | #925 |
| 8 males | #928 |
| treatment symptoms | #928 |
| immunoregulatory effects | #929 |
| epithelial lesions | #929 |
| histopathologic analysis | #930 |
| disease efficacy | #932 |
| normal controls | #933 |
| ophthalmologic surgical | #933 |
| beta1 tumor | #937 |
| epithelialization | #937 |
| iop measured | #939 |
| treatment severe | #940 |
| symptoms evaluated | #941 |
| cytokines epithelial | #941 |
| normal 1 | #943 |
| humans muscarinic | #946 |
| factor production | #946 |
| wheal | #947 |
| mgd | #949 |
| radioallergosorbent test | #949 |
| seasons young | #950 |
| humans lenses | #950 |
| ulcer humans | #952 |
| sensitivity values | #953 |
| scanning confocal | #957 |
| 2 moderate | #957 |
| aldose | #959 |
| 3 eyes | #959 |
| singleagent therapy | #959 |
| endpoint baseline | #960 |
| intracellular infection | #961 |
| sedating | #961 |
| expression 8 | #962 |
| dust mites | #963 |
| observed 3 | #965 |
| eyes 12 | #966 |
| ecp | #967 |
| total score | #968 |
| expression chemokine | #969 |
| positively stained | #971 |
| term therapeutic | #973 |
| basal epithelial | #973 |
| mcp1 gene | #980 |
| day month | #981 |
| 6 males | #983 |
| detected patients | #985 |
| ointment | #989 |
| 4 regulation | #990 |
| primary cultured | #992 |
| carried patients | #993 |
| tenon | #994 |
| observed conclusions | #994 |
| technique 2 | #998 |
| adult cornea | #1001 |
| observed vivo | #1002 |
| methods sixteen | #1002 |
| serum ige | #1005 |
| pediatric subjects | #1008 |
| accommodation ocular | #1009 |
| boyden | #1011 |
| eye infections | #1012 |
| time year | #1012 |
| piperidines pyridines | #1013 |
| allergic diseases | #1014 |
| 1 2 weeks | #1017 |
| blink | #1017 |
| impression | #1019 |
| normal volunteers | #1019 |
| improved 1 | #1020 |
| cells positively | #1021 |
| ω3 fatty acids | #1024 |
| model allergic | #1028 |
| studied prospectively | #1029 |
| induced chemotaxis | #1031 |
| diopter | #1032 |
| improved 3 | #1033 |
| 2 eyes | #1036 |
| 045 ± | #1040 |
| webbased questionnaire | #1040 |
| patching | #1040 |
| chemotaxis | #1042 |
| values analysis | #1043 |
| lysine 4 | #1044 |
| cells fibroblasts | #1044 |
| treatment skin | #1045 |
| concomitantly | #1045 |
| xerophthalmia | #1046 |
| recurrence 6 | #1050 |
| indirect humans | #1050 |
| allergen extracts | #1053 |
| symptoms score | #1054 |
| johnson syndrome | #1057 |
| eyelids | #1059 |
| study therapeutic | #1060 |
| allograft transplantation | #1062 |
| guidelines clinical | #1064 |
| giemsa | #1065 |
| disposable | #1067 |
| staphylococcal enterotoxin | #1067 |
| pollution risk | #1067 |
| noninfectious | #1070 |
| acuity patients | #1071 |
| goblet cell | #1071 |
| immunocytochemical study | #1073 |
| months corrected | #1075 |
| effective treating | #1075 |
| eyes received | #1076 |
| efficacy treatment | #1077 |
| benzamidines | #1079 |
| ade | #1080 |
| syncytial virus | #1080 |
| techniques ophthalmological | #1080 |
| expression icam1 | #1082 |
| allergic inflammatory | #1082 |
| sex matched | #1088 |
| cyclosporine patients | #1091 |
| ige anti | #1098 |
| corrected visual acuity | #1099 |
| assessed vivo | #1104 |
| diseases objective | #1104 |
| endothelium corneal | #1107 |
| 10 males | #1109 |
| meibomian glands | #1110 |
| lens capsule | #1116 |
| rose | #1116 |
| 30 patients | #1118 |
| drops | #1121 |
| keratopathy | #1121 |
| 92 years | #1122 |
| popularization | #1122 |
| periostin | #1125 |
| epithelium female | #1132 |
| clinical findings | #1133 |
| assay fibroblasts | #1133 |
| treatment objective | #1133 |
| cultures human | #1133 |
| anti icam1 | #1134 |
| evaluate therapeutic | #1136 |
| controls examined | #1137 |
| healthy eyes | #1140 |
| visual acuities | #1140 |
| prospective controlled | #1141 |
| small incision | #1143 |
| 4 daily | #1146 |
| p0035 | #1146 |
| minimum angle | #1149 |
| aphakic | #1150 |
| aged phacoemulsification | #1153 |
| cyclosporine humans | #1154 |
| interventional case | #1157 |
| airborne particulate | #1165 |
| sjögrens syndrome | #1171 |
| purpose evaluate | #1171 |
| cornea | #1173 |
| glands sjogren | #1173 |
| immune mechanisms | #1189 |
| ophthalmological female | #1189 |
| fibronectins fibrosis | #1189 |
| adult dermatitis | #1191 |
| levels chemokines | #1191 |
| spatial temporal resolution | #1193 |
| cytokine mrna | #1195 |
| refractory standard | #1207 |
| ded | #1209 |
| 84 ± | #1210 |
| concentrations alpha | #1210 |
| 18 females | #1211 |
| boyden chamber | #1212 |
| lasers excimer | #1215 |
| bengal | #1217 |
| scl | #1219 |
| stevens johnson | #1220 |
| par2 | #1222 |
| 025 | #1223 |
| mmc | #1230 |
| microscopy confocal | #1231 |
| allergic inflammation | #1233 |
| instilled | #1235 |
| correlation clinical | #1240 |
| wearers | #1241 |
| eyes treated | #1242 |
| muc5ac expression | #1249 |
| supply adult | #1254 |
| molecule expressed | #1265 |
| messenger reverse | #1266 |
| levels pge2 | #1270 |
| tomograph | #1271 |
| 4 normal | #1274 |
| period clinical | #1275 |
| anesthesia local | #1278 |
| aged substance | #1286 |
| study eyes | #1286 |
| 169 ± | #1287 |
| lacrimal apparatus | #1288 |
| dermatitis atopic | #1289 |
| phacoemulsification | #1290 |
| iol | #1294 |
| cac | #1300 |
| adult antibiotics | #1301 |
| controls 005 | #1302 |
| dryness | #1303 |
| photorefractive | #1304 |
| spring autumn | #1307 |
| intraocular lenses | #1308 |
| japanese cedar | #1310 |
| thermometry | #1311 |
| allergic | #1314 |
| chemokines chemotaxis | #1316 |
| higher severe | #1316 |
| corneal humans | #1317 |
| presence increased | #1318 |
| expressed secreted | #1321 |
| child chromatography | #1321 |
| ccl11 | #1322 |
| 830 | #1322 |
| membrane increased | #1331 |
| treatment improvements | #1334 |
| prostaglandin production | #1335 |
| light lipid | #1337 |
| ccr3 receptors | #1340 |
| fivepoint scale | #1341 |
| operation patients | #1343 |
| ped | #1348 |
| treatment 14 | #1353 |
| antigen child | #1360 |
| benzalkonium | #1365 |
| responses peripheral | #1371 |
| cytokines dinoprostone | #1374 |
| atopic diseases | #1377 |
| 00001 lower | #1383 |
| timeseries analysis | #1384 |
| ointments | #1396 |
| female glucocorticoids | #1399 |
| 18 eyes | #1399 |
| respiratory pathogen | #1404 |
| epithelial barrier function | #1407 |
| proteaseactivated receptor | #1413 |
| diseases diagnosis | #1413 |
| adult allergens | #1414 |
| normal adults | #1416 |
| 005 1 | #1419 |
| 1 week | #1425 |
| prospective comparative | #1428 |
| higher contrast | #1431 |
| patients cgvhd | #1432 |
| rast | #1434 |
| factors seasons | #1439 |
| corneal neovascularization | #1444 |
| haze | #1444 |
| temperature cell | #1445 |
| reduced 1 | #1451 |
| goblet cells | #1451 |
| macular oedema | #1453 |
| histocytological | #1458 |
| corneal opacity | #1465 |
| lens implantation | #1469 |
| complained | #1470 |
| production il4 | #1481 |
| outcome administration | #1488 |
| corneal edema | #1489 |
| data daily | #1497 |
| 2 minutes | #1498 |
| western cells | #1499 |
| detected frequently | #1499 |
| male metaplasia | #1500 |
| studies suture | #1502 |
| bulbar | #1502 |
| pgd2 | #1505 |
| human corneal | #1507 |
| ophthalmological | #1510 |
| staining | #1514 |
| female fluorescein | #1514 |
| 40 mmhg | #1522 |
| studies glaucoma | #1524 |
| total scores | #1526 |
| eosinophils female | #1527 |
| acuity adult | #1530 |
| inhibitors child | #1533 |
| cells density | #1537 |
| 7 females | #1541 |
| production primary | #1542 |
| cytometric analysis | #1544 |
| dioxide particulate | #1548 |
| virus rsv | #1553 |
| pollen rhinitis | #1559 |
| decreased treatment | #1560 |
| steroidal cell | #1566 |
| aged allergens | #1571 |
| fibronectin laminin | #1573 |
| cells 001 | #1575 |
| 15 females | #1580 |
| purpose investigate | #1581 |
| fibroblasts | #1583 |
| effective long | #1589 |
| assessed quantitative | #1591 |
| aldehyde reductase | #1597 |
| preservative | #1602 |
| ortho aminobenzoates | #1602 |
| cells 0001 | #1603 |
| humans intraocular | #1624 |
| vdt | #1624 |
| incidence adverse events | #1625 |
| weeks administration | #1629 |
| eye | #1630 |
| cyclosporine female | #1637 |
| epstein‐barr virus | #1638 |
| epsteinbarr virus ebv | #1641 |
| mitomycin mmc | #1643 |
| preschool dermatitis | #1644 |
| capsule crystalline | #1654 |
| subjects examined | #1658 |
| prevalence severe | #1662 |
| 10 healthy controls | #1663 |
| syncytial | #1663 |
| reaction young | #1665 |
| damage patients | #1666 |
| function small | #1670 |
| infections fungal | #1673 |
| higher normal | #1674 |
| 2 cytokine | #1685 |
| pm25 levels | #1686 |
| dose equivalent | #1687 |
| confocal middle | #1698 |
| 7 males | #1711 |
| outcome visual | #1713 |
| disease defined | #1713 |
| subjects adolescent | #1716 |
| whitney test | #1721 |
| 744 | #1725 |
| topical application | #1735 |
| cytology | #1741 |
| central corneal | #1741 |
| treatment short | #1742 |
| severity treatment | #1754 |
| years 19 | #1754 |
| antigen anti | #1756 |
| iols | #1760 |
| rsv infection | #1761 |
| eightysix patients | #1764 |
| oral steroids | #1775 |
| inflammation assessed | #1779 |
| enterotoxins female | #1789 |
| alpha sma | #1798 |
| mild cases | #1802 |
| 10 healthy | #1811 |
| endophthalmitis eye | #1815 |
| punctate | #1817 |
| antifungal treatment | #1821 |
| japan methods | #1823 |
| receptor par2 | #1823 |
| regulated activation | #1825 |
| sjs | #1827 |
| eosinophil | #1828 |
| 15 minutes | #1828 |
| child dermatitis | #1832 |
| epithelial damage | #1835 |
| mediator release | #1835 |
| factor tnfalpha | #1836 |
| fibroblasts normal | #1837 |
| corneal transplantation | #1838 |
| degrees 4 | #1839 |
| eye examination | #1840 |
| prostaglandin receptors | #1841 |
| inflammation injections | #1842 |
| month 3 | #1846 |
| effects aged | #1848 |
| receptors prostaglandin | #1853 |
| ulcer female | #1857 |
| 005 differences | #1858 |
| comparative evaluation | #1860 |
| shield | #1860 |
| tnfalpha production | #1862 |
| ari | #1862 |
| humans immunosuppressive | #1874 |
| surgery purpose | #1890 |
| aphakia | #1893 |
| cataract surgery | #1893 |
| ige production | #1900 |
| cells epithelial | #1909 |
| sterilized | #1912 |
| interleukin 4 | #1920 |
| ihc staining | #1923 |
| mast cell degranulation | #1929 |
| contact female | #1935 |
| contribute pathogenesis | #1942 |
| 013 ± | #1943 |
| severe persistent | #1946 |
| protein female | #1946 |
| patients exhibited | #1947 |
| score clinical | #1961 |
| vcam1 expression | #1962 |
| 5 minutes | #1970 |
| 9 males | #1970 |
| 4 males | #1971 |
| comfort | #1972 |
| device treatment | #1972 |
| corrected visual | #1974 |
| gpc | #1974 |
| month 1 | #1975 |
| intraocular | #1977 |
| nonuse | #1979 |
| eyes | #1980 |
| controls p005 | #1984 |
| females age | #1990 |
| studies cell | #1992 |
| irritation | #1994 |
| bak | #1999 |
| reaction serine | #2013 |
| diseases diagnostic | #2014 |
| erosions | #2016 |
| tacrolimus adult | #2023 |
| agents male | #2023 |
| surgery 1 | #2025 |
| ccl5 chemokines | #2026 |
| chemotaxis leukocyte | #2031 |
| increased vegf | #2036 |
| treated eyes | #2038 |
| coherence treatment | #2038 |
| based incidence | #2048 |
| eye female | #2049 |
| corneal topography | #2066 |
| ambient air pollution | #2067 |
| allergens animals | #2067 |
| versus normal | #2067 |
| pollen | #2068 |
| dexamethasone enzyme | #2073 |
| herpetic | #2075 |
| temperature measured | #2078 |
| cytokines enzyme | #2084 |
| ophthalmologic | #2091 |
| cytokines dose | #2093 |
| therapeutic effects | #2106 |
| aged antifungal | #2107 |
| activation normal | #2108 |
| clinical examinations | #2112 |
| cultured chemokine | #2118 |
| average concentrations | #2119 |
| acd | #2127 |
| reaction statistics | #2128 |
| human α | #2132 |
| endopeptidases serine | #2137 |
| docosahexaenoic acid | #2137 |
| mucin2 | #2140 |
| antibody positive | #2142 |
| vegf production | #2143 |
| incidence adverse | #2148 |
| scored | #2157 |
| controls 0001 | #2158 |
| expression patient | #2160 |
| umin | #2163 |
| curve reproducibility | #2164 |
| production inhibited | #2164 |
| virus human | #2170 |
| study flow | #2171 |
| density lower | #2174 |
| pressure iop | #2177 |
| sensation | #2181 |
| dyes humans | #2183 |
| adult administration | #2184 |
| regulation adolescent | #2185 |
| eyes patients | #2186 |
| eye disease | #2190 |
| child computer | #2191 |
| aged mitomycin | #2192 |
| diseases female | #2192 |
| duct obstruction | #2202 |
| pseudophakic | #2208 |
| ulcer patients | #2219 |
| cases severe | #2231 |
| greater concentrations | #2232 |
| 1 3 months | #2234 |
| immunoglobulin male | #2235 |
| upper lower | #2236 |
| matter pm25 | #2243 |
| rater agreement | #2246 |
| vital | #2246 |
| scores correlated | #2247 |
| pollens | #2247 |
| allergic seasonal | #2250 |
| groups difference | #2250 |
| tryptases | #2264 |
| compared vehicle | #2265 |
| individuals adolescent | #2270 |
| myopic | #2271 |
| slit | #2275 |
| il4 il13 | #2279 |
| exposure particulate | #2280 |
| uncorrected | #2284 |
| studies stem | #2285 |
| 6 months | #2290 |
| diseases enzyme | #2294 |
| cooling | #2297 |
| female gels | #2302 |
| humans hypersensitivity | #2311 |
| clinical appearance | #2312 |
| topical treatment | #2312 |
| rsv | #2316 |
| performed treatment | #2323 |
| animal study | #2332 |
| hours dose | #2336 |
| il4 production | #2339 |
| culture supernatants | #2343 |
| weeks 1 | #2344 |
| mann whitney | #2351 |
| ca125 antigen | #2354 |
| method assessing | #2371 |
| syncytial viruses | #2377 |
| skin adolescent | #2378 |
| treatment 2 | #2392 |
| immunosuppressive agents | #2409 |
| relieving | #2410 |
| months initiation | #2412 |
| aged nitrogen | #2415 |
| ophthalmology | #2415 |
| child enzyme | #2420 |
| stevens | #2422 |
| effective patients | #2424 |
| intraocular pressure | #2425 |
| prostaglandin | #2433 |
| interleukin2 receptors | #2456 |
| transcription levels | #2459 |
| sclera | #2464 |
| glaucoma humans | #2492 |
| ige antibody | #2493 |
| fungal female | #2498 |
| enteric coated | #2498 |
| diseases adolescent | #2503 |
| scores clinical | #2510 |
| obstruction male | #2513 |
| histamine | #2514 |
| h1 receptor | #2516 |
| histamine humans | #2533 |
| humans hyperemia | #2535 |
| levels alpha | #2543 |
| ebv | #2546 |
| patients symptoms | #2550 |
| cell expressed | #2557 |
| correlated severity | #2565 |
| methods clinical | #2571 |
| oct | #2571 |
| male polymerase | #2573 |
| flare | #2573 |
| controls serum | #2578 |
| penetrating | #2579 |
| mannwhitney | #2580 |
| vcam1 | #2583 |
| tonometry ocular | #2587 |
| aged myopia | #2593 |
| excimer laser | #2597 |
| methods subjects | #2602 |
| fibroblasts humans | #2610 |
| subjects 12 | #2614 |
| complications adolescent | #2619 |
| baseline treatment | #2620 |
| contact lens | #2624 |
| eosinophilia female | #2629 |
| postsurgical | #2629 |
| 6 months treatment | #2638 |
| lamp | #2646 |
| cyclosporine drug | #2647 |
| cyclosporine csa | #2653 |
| alpha adolescent | #2655 |
| 412 | #2656 |
| administered day | #2664 |
| rantes | #2665 |
| mucins | #2672 |
| cataract extraction | #2683 |
| symptom score | #2687 |
| infections respiratory | #2694 |
| groups differences | #2695 |
| tearing | #2698 |
| bf | #2698 |
| chemokine ccl5 | #2712 |
| studies glucocorticoids | #2717 |
| control eyes | #2721 |
| muc1 | #2726 |
| fibroblasts gene | #2731 |
| alpha vascular | #2735 |
| chemokine production | #2739 |
| hne | #2743 |
| factors chemotaxis | #2746 |
| laser scanning | #2747 |
| tomography oct | #2754 |
| immunocytochemical staining | #2759 |
| betamethasone | #2761 |
| matched normal | #2772 |
| total ige | #2772 |
| atopic female | #2773 |
| chronic graft | #2786 |
| humans immunoenzyme | #2792 |
| symptomatic improvement | #2794 |
| prevention adolescent | #2797 |
| male adolescent | #2813 |
| iop | #2817 |
| scores lower | #2818 |
| whitney | #2819 |
| atopic dermatitis | #2821 |
| higher cases | #2821 |
| dry | #2840 |
| groups normal | #2842 |
| analog scale | #2845 |
| aminobenzoates | #2846 |
| months surgery | #2850 |
| crystalline lens | #2855 |
| treatment 4 | #2868 |
| fibroblasts fibronectins | #2889 |
| qol scores | #2892 |
| syndrome patients | #2902 |
| evaporation rate | #2903 |
| mannwhitney test | #2905 |
| anterior chamber | #2907 |
| test performed | #2907 |
| il1beta | #2910 |
| tests diagnosis | #2922 |
| postoperative follow | #2926 |
| drop | #2927 |
| cgvhd | #2929 |
| surgery 2 | #2932 |
| eye diseases | #2940 |
| interleukin8 il8 | #2953 |
| endophthalmitis | #2955 |
| refraction ocular | #2961 |
| excision | #2987 |
| inter rater | #3000 |
| eosinophils humans | #3014 |
| measured elisa | #3014 |
| normal eyes | #3037 |
| cultured chemokines | #3051 |
| agents interferon | #3054 |
| protease activated | #3059 |
| staining labeling | #3068 |
| safety assessed | #3072 |
| evaporation | #3080 |
| aged anti | #3083 |
| treatment total | #3085 |
| immunologic receptors | #3118 |
| baseline month | #3124 |
| expression adhesion | #3132 |
| rtpcr | #3132 |
| dermatitis | #3150 |
| vehicle | #3153 |
| cells graft | #3163 |
| susceptibility humans | #3175 |
| cell count | #3181 |
| symptom scores | #3181 |
| methods seventy | #3188 |
| 10 patients | #3190 |
| investigate efficacy | #3197 |
| recruited study | #3208 |
| sjogren syndrome | #3228 |
| study medication | #3240 |
| patient global | #3249 |
| cell densities | #3269 |
| accommodation | #3274 |
| acuity | #3280 |
| meniscus | #3289 |
| variance case | #3295 |
| interferometry | #3299 |
| normal control subjects | #3302 |
| intraoperative male | #3322 |
| allergens | #3325 |
| cells assessed | #3332 |
| subjective | #3340 |
| efficacy anti | #3343 |
| diclofenac sodium | #3345 |
| dressings | #3352 |
| histamine receptor | #3356 |
| cellular level | #3367 |
| pfu | #3369 |
| diabetic patients | #3375 |
| fibroblast proliferation | #3377 |
| coherence tomography | #3398 |
| ova | #3409 |
| instillation | #3411 |
| normal subjects | #3415 |
| air pollutants | #3416 |
| alpha cell | #3440 |
| patients obstructive | #3460 |
| host disease humans | #3469 |
| papilla | #3493 |
| cataract | #3514 |
| local excision | #3555 |
| interleukin8 male | #3570 |
| visual analog | #3572 |
| agents steroidal | #3585 |
| sjogren | #3591 |
| tokyo | #3609 |
| immunoglobulin ige | #3614 |
| signs | #3617 |
| agents incidence | #3623 |
| plaque formation | #3626 |
| weeks surgery | #3640 |
| method enzyme | #3648 |
| pressure male | #3653 |
| cell density | #3654 |
| fiftytwo patients | #3661 |
| adult chronic | #3668 |
| disease adolescent | #3694 |
| vegf mrna | #3694 |
| 016 ± | #3698 |
| cytological | #3709 |
| 29 years | #3711 |
| gels humans | #3720 |
| week 1 | #3745 |
| adult air | #3751 |
| suture techniques | #3751 |
| signs symptoms | #3758 |
| pm25 | #3770 |
| situ nickend | #3772 |
| helper type | #3773 |
| management disease | #3773 |
| anterior segment | #3782 |
| hydrochloride | #3792 |
| lenses | #3815 |
| docosahexaenoic acid dha | #3823 |
| perennial | #3824 |
| patients examined | #3835 |
| amniotic | #3843 |
| studies severity | #3851 |
| intercellular adhesion molecule | #3865 |
| interleukin13 | #3866 |
| strabismus | #3900 |
| diseases study | #3906 |
| complications observed | #3914 |
| mann | #3916 |
| interleukin2 interleukin4 | #3949 |
| specific ige | #3951 |
| subjects included | #3968 |
| cell expression | #3989 |
| chemokines | #3992 |
| microscopy | #3992 |
| discontinued treatment | #3993 |
| break | #3994 |
| lower compared | #3996 |
| studies roc | #3998 |
| ulcer | #4009 |
| cells hla | #4035 |
| female flow | #4036 |
| echinocandins | #4040 |
| acrylic resins | #4047 |
| immunosuppressive | #4068 |
| readings | #4071 |
| steroid | #4091 |
| subjects methods | #4093 |
| steroid treatment | #4095 |
| acinar | #4097 |
| discontinue | #4100 |
| inflammatory disorders | #4103 |
| tended higher | #4106 |
| ige | #4116 |
| bronchial asthma | #4135 |
| th2 | #4137 |
| severe effects | #4168 |
| female glaucoma | #4179 |
| aged sensitivity | #4189 |
| α induced | #4193 |
| papillary | #4193 |
| male surveys | #4211 |
| measured enzyme | #4218 |
| percentages | #4223 |
| visual acuity | #4239 |
| gamma interleukin1 | #4281 |
| heidelberg | #4286 |
| adult antibody | #4327 |
| purpose report | #4328 |
| clinically diagnosed | #4349 |
| visual function | #4360 |
| edema | #4368 |
| effective improving | #4382 |
| 11 patients | #4410 |
| reaction rna | #4417 |
| infiltrates | #4459 |
| interleukin | #4482 |
| healed | #4489 |
| conclusions clinical | #4503 |
| studies environmental | #4513 |
| scores | #4515 |
| gamma interleukin4 | #4530 |
| 14 28 | #4549 |
| baseline 2 | #4575 |
| excimer | #4592 |
| viral respiratory | #4601 |
| surface reconstruction | #4608 |
| blinding | #4654 |
| years recruited | #4660 |
| lid | #4671 |
| cytometric | #4683 |
| studies prosthesis | #4704 |
| patients bilateral | #4711 |
| chemotactic | #4713 |
| treatment conclusions | #4714 |
| 4 9 | #4720 |
| tomography optical | #4729 |
| immunoenzyme | #4748 |
| dermatitis contact | #4754 |
| 36 years | #4755 |
| 80 child | #4790 |
| glaucoma patients | #4793 |
| purpose assess | #4807 |
| healthy control subjects | #4826 |
| patients administration | #4833 |
| 111 patients | #4837 |
| immunoenzyme techniques | #4857 |
| protein array | #4864 |
| allergy | #4868 |
| fluoresceins fluorescent | #4892 |
| adult biological | #4902 |
| chronic gvhd | #4913 |
| foreign body | #4922 |
| defensins | #4929 |
| infrared rays | #4946 |
| scale 0 | #4948 |
| logarithm | #4974 |
| lower density | #5019 |
| months treatment | #5023 |
| nitrogen dioxide | #5023 |
| optical coherence | #5029 |
| groups compared | #5036 |
| opacities | #5052 |
| enterotoxins | #5054 |
| safety treatment | #5056 |
| unpaired | #5095 |
| amnion | #5097 |
| induced male | #5101 |
| strip | #5103 |
| lipopeptides | #5119 |
| glaucoma | #5131 |
| purposewe | #5143 |
| receptors chemokine | #5174 |
| patients 100 | #5189 |
| steroids | #5194 |
| epithelium | #5224 |
| thirtysix patients | #5224 |
| observed 2 | #5246 |
| determine efficacy | #5268 |
| lysine male | #5269 |
| child combined | #5301 |
| analysis reverse | #5302 |
| 2 weeks | #5303 |
| enzyme linked | #5314 |
| time measurements | #5318 |
| 74 years | #5320 |
| humans hyperthermia | #5365 |
| imidazoles male | #5366 |
| 20 25 | #5367 |
| allergen | #5403 |
| metaplasia | #5404 |
| agents chronic | #5423 |
| factors visual | #5431 |
| procedures postoperative | #5475 |
| differential disease | #5487 |
| igg anti | #5508 |
| keratitis | #5509 |
| alum | #5527 |
| mucin1 | #5530 |
| treatment follow | #5537 |
| barr virus | #5547 |
| humans lasers | #5560 |
| epithelial barrier | #5584 |
| counted | #5606 |
| visual analog scale | #5621 |
| spearman correlation | #5634 |
| aims evaluate | #5656 |
| giant | #5659 |
| publication administration | #5662 |
| il13 | #5676 |
| sutures | #5684 |
| eye proteins | #5692 |
| opacity | #5697 |
| histamine antagonists | #5721 |
| tonometry | #5735 |
| techniques cells | #5746 |
| th2 cells | #5747 |
| grades | #5747 |
| adult cell | #5754 |
| 889 | #5801 |
| male time | #5839 |
| tgfbeta1 | #5853 |
| sickness impact | #5861 |
| icam1 | #5871 |
| agents candida | #5881 |
| score 3 | #5903 |
| biomarkers case | #5924 |
| expression alpha | #5963 |
| nsaid | #5969 |
| antibody anti | #5999 |
| microscopy study | #6002 |
| chemotactic factors | #6005 |
| ip10 | #6027 |
| adverse health effects | #6035 |
| rhinitis allergic | #6041 |
| humans hyaluronic | #6046 |
| higher compared | #6074 |
| exacerbate | #6114 |
| controlled clinical | #6123 |
| baseline 1 | #6145 |
| placebo treatment | #6146 |
| thickening | #6158 |
| male neutrophils | #6171 |
| patients refractory | #6181 |
| treatment adverse | #6199 |
| desiccation | #6204 |
| resultsthe | #6224 |
| genetic adolescent | #6226 |
| diagnostic techniques | #6234 |
| efficacy | #6247 |
| impact profile | #6258 |
| subjects randomized | #6267 |
| johnson | #6274 |
| steroidal | #6295 |
| cells lymphocytes | #6296 |
| patients control | #6337 |
| dosed | #6343 |
| allergies | #6348 |
| ocular hypertension | #6376 |
| 005 conclusion | #6428 |
| ulceration | #6435 |
| japan male | #6443 |
| asthmatic agents | #6445 |
| wearing | #6466 |
| 2 groups | #6475 |
| air pollution | #6514 |
| rejection humans | #6543 |
| house dust | #6543 |
| primary human | #6559 |
| diclofenac | #6566 |
| 3 groups | #6582 |
| anti asthmatic | #6611 |
| glucocorticoids humans | #6618 |
| linked immunosorbent | #6618 |
| 3 months | #6643 |
| conventional therapy | #6652 |
| immunosorbent assay | #6675 |
| months compared | #6704 |
| humans japan | #6704 |
| inflammatory | #6764 |
| chemokine | #6774 |
| graded | #6779 |
| breakup | #6780 |
| severe | #6799 |
| serum total | #6811 |
| 1 14 | #6842 |
| male microscopy | #6859 |
| treatment refractory | #6864 |
| bcva | #6877 |
| enzymelinked immunosorbent assay | #6904 |
| conventional treatment | #6981 |
| wear | #7013 |
| adhesion molecules | #7016 |
| years treated | #7049 |
| contrast sensitivity | #7060 |
| observed treatment | #7063 |
| humans hypothermia | #7079 |
| 6 patients | #7102 |
| epsteinbarr virus | #7188 |
| transplantation child | #7270 |
| patients 9 | #7284 |
| water loss | #7310 |
| infections herpesvirus | #7328 |
| viral female | #7329 |
| treatment period | #7342 |
| syndromes | #7375 |
| photography | #7394 |
| severity | #7473 |
| relief | #7481 |
| seasonal | #7483 |
| alpha regulation | #7520 |
| confocal microscopy | #7575 |
| epithelial | #7618 |
| humans immunoglobulin | #7674 |
| inflammatory agents | #7677 |
| autumn | #7680 |
| treatment decreased | #7714 |
| calcineurin inhibitors | #7727 |
| 16 patients | #7794 |
| hyperthermia induced | #7892 |
| cyclosporine | #7933 |
| epstein barr | #8024 |
| steroidal anti | #8072 |
| tnfalpha | #8140 |
| methods fifty | #8160 |
| fk506 | #8206 |
| aged minimally | #8301 |
| barr | #8314 |
| production human | #8367 |
| assess safety | #8419 |
| evaluate effectiveness | #8448 |
| purpose | #8455 |
| patients normal | #8497 |
| regulation vascular | #8551 |
| statistically differences | #8556 |
| hypothermia induced | #8648 |
| graft rejection | #8670 |
| hladr | #8682 |
| corticosteroid | #8683 |
| epithelial cells | #8827 |
| score 1 | #8860 |
| design prospective | #8861 |
| year male | #8873 |
| ceramides | #8893 |
| capsular | #8909 |
| ovalbumin | #8972 |
| silicone | #8991 |
| anti inflammatory | #9041 |
| surgical flaps | #9087 |
| 3 6 | #9098 |
| complaints | #9098 |
| illness adolescent | #9141 |
| immunosorbent | #9162 |
| humidity | #9176 |
| cutoff values | #9181 |
| patients 16 | #9191 |
| 4 12 | #9193 |
| treatment adolescent | #9195 |
| 0 3 | #9331 |
| wilcoxon | #9408 |
| 375 | #9414 |
| virus ebv | #9435 |
| 8 patients | #9463 |
| humans intraoperative | #9556 |
| hypersensitivity | #9569 |
| reaction tumor | #9638 |
| adult anti | #9709 |
| particulate matter | #9803 |
| superficial | #9826 |
| refraction | #9835 |
| methods prospective | #9836 |
| anesthetics local | #9840 |
| limbic | #9855 |
| fluorescent dyes | #9935 |
| term treatment | #10001 |
| objectively | #10055 |
| postoperatively | #10097 |
| technique indirect | #10132 |
| symptoms patients | #10143 |
| 1year followup | #10154 |
| 10 minutes | #10161 |
| foreign | #10171 |
| factor vegf | #10178 |
| biomarkers child | #10229 |
| antigens humans | #10284 |
| compared treatment | #10317 |
| rhinitis | #10337 |
| glands | #10364 |
| cytokines | #10378 |
| week 4 | #10414 |
| common complication | #10417 |
| questionnaire | #10420 |
| shortterm | #10427 |
| mast cells | #10496 |
| lens | #10588 |
| subjects age | #10599 |
| longterm treatment | #10644 |
| chamber | #10647 |
| male prospective | #10703 |
| volunteers | #10707 |
| substance | #10715 |
| compared controls | #10729 |
| nsaids | #10777 |
| cells th2 | #10778 |
| filtering | #10900 |
| metabolism male | #10953 |
| il5 | #11022 |
| examinations | #11187 |
| patient demographics | #11192 |
| 20 40 | #11212 |
| body temperature | #11219 |
| complications retrospective | #11251 |
| eczema | #11287 |
| patients 4 | #11337 |
| purposeto | #11381 |
| nonsteroidal | #11393 |
| corrected | #11394 |
| mast | #11549 |
| interleukin8 | #11599 |
| eosinophilic | #11723 |
| adjunctive | #11730 |
| receptors immunologic | #11956 |
| longterm outcomes | #12069 |
| evaluate | #12086 |
| grading | #12107 |
| coherence | #12125 |
| prospective | #12163 |
| 0001 conclusions | #12216 |
| csa | #12259 |
| asthmatic | #12282 |
| sickness | #12312 |
| tnf α | #12395 |
| thirty | #12576 |
| volunteers humans | #12586 |
| evaluate effects | #12612 |
| elisa | #12717 |
| mucous | #12766 |
| tnfα | #12781 |
| agents anti | #12822 |
| evaluate safety | #12879 |
| host disease | #12922 |
| seconds | #13199 |
| minutes | #13216 |
| complications diabetes | #13262 |
| epithelia | #13267 |
| 4 weeks | #13267 |
| 005 | #13326 |
| tests performed | #13356 |
| 1 3 | #13413 |
| 2 cases | #13447 |
| underwent | #13549 |
| western blot analysis | #13578 |
| prosthesis design | #13600 |
| cultured coculture | #13613 |
| particulate | #13632 |
| clinical examination | #13829 |
| life surveys | #13937 |
| mast cell | #13997 |
| study clinical | #14017 |
| dogs female | #14046 |
| graft host | #14084 |
| 60 patients | #14391 |
| myopia | #14577 |
| diseases diabetes | #14729 |
| vascular cell | #14846 |
| spearman | #14877 |
| implantation | #14889 |
| infections staphylococcus | #15065 |
| hyaluronic | #15111 |
| allograft | #15158 |
| patients follow | #15344 |
| visual | #15382 |
| refractory | #15389 |
| burning | #15485 |
| discontinued | #15495 |
| 1 2 | #15658 |
| longterm | #15717 |
| 006 | #15839 |
| graft | #15913 |
| tnf alpha | #16084 |
| radiation injuries | #16251 |
| patients divided | #16456 |
| 32 patients | #16659 |
| 15 patients | #16684 |
| adhesion molecule1 | #16940 |
| herpesvirus 4 | #16966 |
| evaluate efficacy | #17035 |
| 4 human | #17084 |
| patients assigned | #17274 |
| noninvasive | #17324 |
| molecule1 | #17435 |
| antibiotics antineoplastic | #17587 |
| histopathologic | #17743 |
| acid male | #17891 |
| method female | #17912 |
| anterior | #17986 |
| symptoms | #18008 |
| inflammation | #18029 |
| healthy | #18209 |
| morphologic | #18280 |
| alkylating | #18391 |
| stained | #18391 |
| vegf | #18469 |
| 0001 | #18534 |
| cold temperature | #18622 |
| 00001 | #18681 |
| 9 patients | #18689 |
| neovascularization | #19381 |
| female fluorescent | #19461 |
| stromal | #19499 |
| aged postoperative | #19510 |
| lipids male | #19666 |
| endothelial growth | #19723 |
| nerve fibers | #19872 |
| follow period | #19917 |
| artificial | #20012 |
| female graft | #20067 |
| 24 patients | #20143 |
| count cell | #20148 |
| epithelial cell | #20437 |
| complications prospective | #20558 |
| patients evaluated | #20800 |
| 22 patients | #21524 |
| 003 | #21648 |
| daily | #22391 |
| gland | #22647 |
| followup period | #22674 |
| male middle aged | #22802 |
| ifngamma | #23824 |
| outcome measures | #24510 |
| enrolled | #24838 |
| transplantation homologous | #25557 |
| patients adolescent | #25760 |
| adult body | #25783 |
| adult analysis | #26261 |
| conclusions patients | #26516 |
| adult biomarkers | #29382 |
| statistically | #29861 |
| age matched | #29948 |
| humans inflammation | #30660 |
| cells female | #31500 |
Relatório de execução | |
Prominent publications by Hiroshi Fujishima
KOL-Index: 19369
PURPOSE: To describe MUC5AC alterations and the ocular surface disorder in atopic patients with or without corneal ulcers.
METHODS: Atopic patients' eyes were divided into two groups according to the presence and absence of corneal ulceration. The subjects underwent corneal sensitivity measurements, Schirmer test, tear film break-up time (BUT), fluorescein and Rose Bengal staining of the ocular surface and conjunctival impression cytology and brush cytology. Impression cytology samples ...
| Conhecido por Ocular Surface | Eyes Corneal Ulcers | Atopic Patients | Brush Cytology | Akc Vkc |
Application of Visante Optical Coherence Tomography Tear Meniscus Height Measurement in the Diagnosis of Dry Eye Disease
[ PUBLICATION ]
PURPOSE: To investigate the applicability of tear meniscus height (TMH) measurement using Visante optical coherence tomography (OCT) in the diagnosis of dry eye disease.
DESIGN: Prospective, controlled, single-center study.
PARTICIPANTS: Twenty-four right eyes of 24 patients (6 males, 18 females; mean age, 63.14±13.4 years) with definite dry eye according to the Japanese dry eye diagnostic criteria and 27 right eyes of 27 control subjects (12 males, 15 females; mean age, 56.04±14.22 ...
| Conhecido por Dry Eye Disease | Coherence Tomography | Tear Meniscus Height | Sensitivity Specificity | Strip Meniscometry |
Evaluation of lipid oxidative stress status and inflammation in atopic ocular surface disease.
[ PUBLICATION ]
BACKGROUND: Although the oxidative stress status in atopic skin disease has been reported to be elevated, there are still no studies related to the status of oxidative stress in atopic ocular surface disease. The purpose of this study was to evaluate the ocular surface lipid oxidative stress status and inflammation in atopic keratoconjunctivitis (AKC) patients and normal subjects.
METHODS: Twenty eight eyes of 14 patients (9 males, 5 females) with AKC and 18 eyes of 9 age and sex matched ...
| Conhecido por Oxidative Stress | Akc Patients | Surface Disease | Inflammatory Cells | 5 Females |
KOL-Index: 11411
PURPOSE: To evaluate the effectiveness and safety of a novel cyclosporine 0.1% aqueous ophthalmic solution in a large population with vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC).
METHODS: A prospective observational postmarketing study was initiated in Japan. A total of 594 patients with VKC or AKC were started on this drug within 1 year after market launch (January 2006) and completed a 6-month follow-up. These patients were observed clinically, and ...
| Conhecido por Vkc Akc | Allergic Conjunctivitis | Topical Steroids | 1 Month | Objective Signs |
Alterations of the ocular surface epithelial MUC16 and goblet cell MUC5AC in patients with atopic keratoconjunctivitis
[ PUBLICATION ]
BACKGROUND: An increased understanding of the ocular surface at cellular level in the conjunctiva and the cornea may help explain the pathogenesis and the subsequent clinical appearance of atopic ocular allergies, which may be potentially blinding.
PURPOSE: To investigate the MUC16 and MUC5AC alterations, tear function and the ocular surface disorder in patients with atopic keratoconjunctivitis (AKC).
METHODS: Thirty-six eyes of 18 AKC patients as well as 28 eyes of 14 age- and ...
| Conhecido por Atopic Keratoconjunctivitis | Ocular Surface | Patients Akc | Muc5ac Muc16 | Goblet Cell |
KOL-Index: 10572
BACKGROUND: The pathogenesis of the ocular surface disease in atopic keratoconjunctivitis (AKC) and vernal keratoconjunctivitis (VKC) has not been fully understood. We tried to clarify the differences in the ocular surface status in patients with AKC, VKC, and healthy control subjects.
METHODS: Twenty-four eyes of 12 AKC patients, 12 eyes of six VKC patients, and 20 eyes of 10 normal control subjects were studied. The subjects underwent corneal sensitivity measurements, Schirmer test, ...
| Conhecido por Ocular Surface | Atopic Keratoconjunctivitis | Patients Akc | Eyes Vkc | Brush Cytology |
Alterations of the ocular surface epithelial mucins 1, 2, 4 and the tear functions in patients with atopic keratoconjunctivitis
[ PUBLICATION ]
BACKGROUND: An increased understanding of the ocular surface alterations at the cellular level in the conjunctiva and the cornea, may help explain the pathogenesis and the subsequent clinical appearance of atopic ocular allergies, which may be potentially blinding.
PURPOSE: To investigate MUC 1, 2 and 4 alterations, tear function and the ocular surface disorder in patients with atopic keratoconjunctivitis.
METHODS: Twenty-eight eyes of 14 atopic keratoconjunctivitis patients as well as ...
| Conhecido por Atopic Keratoconjunctivitis | Ocular Surface | Brush Cytology | Corneal Sensitivity | Epithelial Mucins |
KOL-Index: 10372
PURPOSE: To prospectively assess the clinical outcome after implantation of the 1CU accommodating intraocular lens (IOL) and a foldable acrylic IOL (AcrySof, Alcon).
SETTING: Department of Ophthalmology, Tokyo Dental College, Ichikawa Hospital, Ichikawa, and Minami Aoyama Eye Clinics, Tokyo, Yokohama, Japan.
METHODS: Twenty-two eyes of 16 patients with cataract had phacoemulsification implantation of 1CU accommodating IOL. Twenty eyes of 10 age-matched and sex-matched patients with ...
| Conhecido por Intraocular Lens | Visual Acuity | 1cu Iol | Cataract Surgery | Amplitude Accommodation |
KOL-Index: 10324
PURPOSE: Eosinophils are known to have important roles in the pathogenesis of allergic conjunctivitis. Prostaglandin (PG) D2, which has been implicated as a factor in allergic diseases, is known to have chemotactic activity for eosinophils. Its receptor, chemoattractant receptor homologous molecule expressed on TH2 (CRTH2), serves as a receptor for PGD2 and has been reported to mediate PGD2-dependent migration of eosinophils. In the present study, both eosinophil toxic activity for ...
| Conhecido por Receptor Crth2 | Chemotaxis Eosinophils | Allergic Conjunctivitis | Pgd2dependent Migration | Homologous Molecule |
A Randomized, Placebo-Controlled Clinical Trial of Tacrolimus Ophthalmic Suspension 0.1% in Severe Allergic Conjunctivitis
[ PUBLICATION ]
AIMS: To examine the efficacy of tacrolimus ophthalmic suspension 0.1% in treating severe allergic conjunctivitis.
METHODS: This was a multicenter, randomized, double-masked, placebo-controlled clinical trial. Fifty-six patients with severe allergic conjunctivitis in whom topical antiallergic agents and corticosteroids had been ineffective were randomized to tacrolimus or placebo treatment. Patients were treated either with tacrolimus or placebo twice-daily for 4 weeks. Severity of ...
| Conhecido por Severe Allergic Conjunctivitis | Tacrolimus Ophthalmic | Objective Signs | Corneal Involvement | Clinical Trial |
TGF-beta1, IL-1beta, and Th2 cytokines stimulate vascular endothelial growth factor production from conjunctival fibroblasts
[ PUBLICATION ]
Giant papillary formation containing newly formed vessels is a major characteristic of severe allergic conjunctivitis, such as atopic keratoconjunctivitis (AKC) or vernal keratoconjunctivitis (VKC). We examined production of vascular endothelial growth factor (VEGF) from cultured conjunctival fibroblasts from normal volunteers under stimulation with type 1-, type 2-helper T cell derived and proinflammatory cytokines to investigate the mechanism of giant papillae formation in AKC/VKC. ...
| Conhecido por Conjunctival Fibroblasts | Vascular Endothelial | Growth Factor | Vegf Concentration | Akc Vkc |
KOL-Index: 9650
PURPOSE: To prospectively assess the clinical and visual outcomes of phacoemulsification and implantation of a rollable intraocular lens (IOL) with a thin optic and compare the results with those of implantation of a foldable acrylic IOL.
SETTING: Department of Ophthalmology, Tokyo Dental College, Ichikawa General Hospital, Ichikawa, Chiba, Japan.
METHODS: Sixteen consecutive eyes of 8 patients (4 women, 4 men) with corticonuclear cataract had small-incision clear corneal ...
| Conhecido por Intraocular Lens | Thinoptx Iol | Phacoemulsification Implantation | Visual Acuity | 6 Months |
Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease
[ PUBLICATION ]
We investigated the effect of 0.05% topical cyclosporine (Cys) on the ocular surface and tear functions in dry eye patients with chronic GVHD (cGVHD) in a prospective comparative study. Thirty eyes of 15 patients refractory to baseline treatment were recruited and the patients assigned for topical Cys treatment group (14 eyes of 7 patients) and control group (12 eyes of 6 patients) respectively. Two patients dropped out because of intolerable irritation while using topical Cys eye drops. ...
| Conhecido por Ocular Surface | Topical Cyclosporine | Eye Patients | Chronic Graft | Host Disease |
Measurement of IL‐4 in tears of patients with seasonal allergic conjunctivitis and vernal keratoconjunctivitis
[ PUBLICATION ]
To elucidate the mechanism of ocular surface allergic disease, we focused on IL-4, which is one of the key factors in regulating IgE production, and thus determined the concentration of IL-4 in tears. IL-4 concentration was determined in the tears of 15 patients with seasonal allergic conjunctivitis, 15 vernal keratoconjunctivitis (VKC), 10 giant papillary conjunctivitis (GPC), 10 patients with non-allergic conjunctivitis and post-cataract surgical conjunctivitis as intermediate ...
| Conhecido por Allergic Conjunctivitis | Tears Patients | Vkc Gpc | Normal Controls | Linked Immunosorbent |
Pessoas importantes para Allergic Conjunctivitis
Principais kols do mundo
Selecione uma frase de pesquisa allergic conjunctivitis , allergic conjunctivitis asthma , allergic conjunctivitis mice , allergic conjunctivitis children , allergic conjunctivitis patients
Hiroshi Fujishima:Impacto especializado
Conceitos para os quaisHiroshi Fujishimatem influência direta:Allergic conjunctivitis, Dry eye, Atopic keratoconjunctivitis, Conjunctival fibroblasts, Allergic conjunctival disease, Brush cytology, Ocular surface, Vernal keratoconjunctivitis.
Hiroshi Fujishima:Kol Impact
Conceitos relacionados ao trabalho de outros autores para os quaisfor which Hiroshi Fujishima tem influência:Dry eye, Ocular surface, Allergic conjunctivitis, Tear film, Amniotic membrane, Cataract surgery, Contact lens.
Tools
Este é o seu perfil? Reivindique seu perfil Copiar URL Incorporar link para o seu perfil |